SPT - Interim / Quarterly Report 2025

SCINOPHARM TAIWAN, LTD. AND SUBSIDIARIES

CONSOLIDATED FINANCIAL STATEMENTS AND INDEPENDENT AUDITORS’ REVIEW REPORT SEPTEMBER 30, 2025 AND 2024

For the convenience of readers and for information purpose only, the auditors’ report and the accompanying financial statements have been translated into English from the original Chinese version prepared and used in the Republic of China. In the event of any discrepancy between the English version and the original Chinese version or any differences in the interpretation of the two versions, the Chinese-language auditors’ report and financial statements shall prevail.

~1~

SCINOPHARM TAIWAN, LTD. AND SUBSIDIARIES

SEPTEMBER 30, 2025 AND 2024 CONSOLIDATED FINANCIAL STATEMENTS AND INDEPENDENT AUDITORS’ REVIEW REPORT TABLE OF CONTENTS

Contents	Page
1. Cover Page 2. Table of Contents 3. Independent Auditors’ Review Report 4. Consolidated Balance Sheets 5. Consolidated Statements of Comprehensive Income 6. Consolidated Statements of Changes in Equity 7. Consolidated Statements of Cash Flows 8. Notes to the Consolidated Financial Statements (1) HISTORY AND ORGANISATION (2) THE DATE OF AUTHORISATION FOR ISSUANCE OF THE CONSOLIDATED FINANCIAL STATEMENTS AND PROCEDURES FOR AUTHORISATION (3) APPLICATION OF NEW STANDARDS, AMENDMENTS AND INTERPRETATIONS (4) SUMMARY OF MATERIAL ACCOUNTING POLICIES (5) CRITICAL ACCOUNTING JUDGEMENTS, ESTIMATES AND	1 2 ~ 3 4 ~ 6 7 ~ 8 9 10 11 ~ 12 13 ~ 54 13 13 13 ~ 14 15 ~ 16 16

Contents

Page

1. Cover Page
2. Table of Contents
3. Independent Auditors’ Review Report
4. Consolidated Balance Sheets
5. Consolidated Statements of Comprehensive Income
6. Consolidated Statements of Changes in Equity
7. Consolidated Statements of Cash Flows
8. Notes to the Consolidated Financial Statements
(1)
HISTORY AND ORGANISATION
(2)
THE DATE OF AUTHORISATION FOR ISSUANCE OF THE
CONSOLIDATED FINANCIAL STATEMENTS AND
PROCEDURES FOR AUTHORISATION
(3)
APPLICATION OF NEW STANDARDS, AMENDMENTS AND
INTERPRETATIONS
(4)
SUMMARY OF MATERIAL ACCOUNTING POLICIES
(5)
CRITICAL ACCOUNTING JUDGEMENTS, ESTIMATES AND

1
2 ~ 3
4 ~ 6
7 ~ 8
9
10
11 ~ 12
13 ~ 54
13
13
13 ~ 14
15 ~ 16
16

~2~

Contents Page

	KEY SOURCES OF ASSUMPTION UNCERTAINTY
(6)	DETAILS OF SIGNIFICANT ACCOUNTS	17 ~ 41
(7)	RELATED PARTY TRANSACTIONS	41 ~ 42
(8)	PLEDGED ASSETS	42
(9)	SIGNIFICANT CONTINGENT LIABILITIES AND	43
	UNRECOGNISED CONTRACT COMMITMENTS
(10)	SIGNIFICANT DISASTER LOSS	43
(11)	SIGNIFICANT EVENTS AFTER THE BALANCE SHEET DATE	43
(12)	OTHERS	43 ~ 52
(13)	SUPPLEMENTARY DISCLOSURES	52
	A. Significant transactions information	52
	B. Information on investees	52
	C. Information on investments in Mainland China	52
(14)	SEGMENT INFORMATION	52 ~ 54

~3~

INDEPENDENT AUDITORS’ REVIEW REPORT TRANSLATED FROM CHINESE

To the Board of Directors and Shareholders of ScinoPharm Taiwan, Ltd.

Introduction

We have reviewed the accompanying consolidated balance sheets of ScinoPharm Taiwan, Ltd. and subsidiaries (the “Group”) as at September 30, 2025 and 2024, and the related consolidated statements of comprehensive income for the three-month and nine-month periods then ended, as well as the consolidated statements of changes in equity and of cash flows for the nine-month periods then ended, and notes to the consolidated financial statements, including a summary of material accounting policies. Management is responsible for the preparation and fair presentation of these consolidated financial statements in accordance with the Regulations Governing the Preparation of Financial Reports by Securities Issuers and International Accounting Standard 34, “Interim Financial Reporting” that came into effect as endorsed by the Financial Supervisory Commission. Our responsibility is to express a conclusion on these consolidated financial statements based on our reviews.

Scope of review

Except as explained in the following paragraph, we conducted our reviews in accordance with the Standard on Review Engagements 2410, “Review of Financial Information Performed by the Independent Auditor of the Entity” of the Republic of China. A review of consolidated financial statements consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

~4~

Basis for qualified conclusion

The financial statements of certain insignificant consolidated subsidiaries and supplementary disclosures in Note 13 were not reviewed by independent auditors. Those statements reflect total － assets of $18,059 thousand and $28,612 thousand, both constituting % of the consolidated total － assets, and total liabilities of $973 thousand and $9,576 thousand, constituting % and 1% of the consolidated total liabilities as at September 30, 2025 and 2024, respectively, and total comprehensive income (loss) of $1,148 thousand, $553 thousand, ($304) thousand and $2,022 thousand, constituting －－ %, 1%, % and 1% of the consolidated total comprehensive income for the three-month and ninemonth periods then ended, respectively.

Qualified conclusion

Except for the adjustments to the consolidated financial statements, if any, as might have been determined to be necessary had the financial statements of certain insignificant subsidiaries and supplementary disclosures in Note 13 been reviewed by independent auditors as described in the Basis for qualified conclusion section above, based on our reviews, nothing has come to our attention that causes us to believe that the accompanying consolidated financial statements do not present fairly, in all material respects, the consolidated financial position of the Group as at September 30, 2025 and 2024, and its consolidated financial performance for the three-month and nine-month periods then ended and its consolidated cash flows for the nine-month periods then ended in accordance with the Regulations Governing the Preparation of Financial Reports by Securities Issuers and International Accounting Standard 34, “Interim Financial Reporting” that came into effect as endorsed by the Financial Supervisory Commission.

~5~

Yeh, Fang-Ting

Independent Auditors

Hsu, Hui-Yu

PricewaterhouseCoopers, Taiwan Republic of China November 3, 2025

------------------------------------------------------------------------------------------------------------------------------The accompanying consolidated financial statements are not intended to present the financial position and results of operations and cash flows in accordance with accounting principles generally accepted in countries and jurisdictions other than the Republic of China. The standards, procedures and practices in the Republic of China governing the audit of such financial statements may differ from those generally accepted in countries and jurisdictions other than the Republic of China. Accordingly, the accompanying consolidated financial statements and independent auditors’ report are not intended for use by those who are not informed about the accounting principles or auditing standards generally accepted in the Republic of China, and their applications in practice.

As the financial statements are the responsibility of the management, PricewaterhouseCoopers cannot accept any liability for the use of, or reliance on, the English translation or for any errors or misunderstandings that may derive from the translation.

~6~

SCINOPHARM TAIWAN, LTD. AND SUBSIDIARIES CONSOLIDATED BALANCE SHEETS

SEPTEMBER 30, 2025, DECEMBER 31, 2024 AND SEPTEMBER 30, 2024

(Expressed in thousands of New Taiwan dollars)

Assets	Notes	September 30, 2025 AMOUNT % `$` `2,850,745 23` `-` `-` `77,480` `1` `378,726` `3` `22,502` `-` `1,904,457 16` `178,499` `1` `5,412,409 44` `1,952,113 16` `3,423,328 28` `676,471` `5` `16,761` `-` `649,229` `5` `87,827` `1` `2,995` `-` `29,270` `-` `61,546` `1` `6,899,540 56` `$` `12,311,949 100` (Continued)	December 31, 2024 AMOUNT % `$` `4,165,987` `35` `-` `-` `29,397` `-` `604,219` `5` `20,572` `-` `1,673,007` `14` `114,908` `1` `6,608,090` `55` `70,134` `1` `3,738,889` `32` `686,635` `6` `17,130` `-` `625,260` `5` `150,890` `1` `2,367` `-` `30,940` `-` `12,403` `-` `5,334,648` `45` `$` `11,942,738` `100`	September 30, 2024	September 30, 2024
		AMOUNT `$` `2,850,745` `-` `77,480` `378,726` `22,502` `1,904,457` `178,499` `5,412,409` `1,952,113` `3,423,328` `676,471` `16,761` `649,229` `87,827` `2,995` `29,270` `61,546` `6,899,540` `$` `12,311,949` (Continued)	AMOUNT `$` `4,165,987` `-` `29,397` `604,219` `20,572` `1,673,007` `114,908` `6,608,090` `70,134` `3,738,889` `686,635` `17,130` `625,260` `150,890` `2,367` `30,940` `12,403` `5,334,648` `$` `11,942,738`	AMOUNT `$` `3,975,691` `1,974` `-` `445,565` `29,346` `1,876,599` `157,927` `6,487,102` `74,564` `3,702,367` `688,527` `22,614` `637,515` `138,290` `2,385` `30,940` `-` `5,297,202` `$` `11,784,304`	%
Current assets 1100 Cash and cash equivalents 1110 Financial assets at fair value through profit or loss - current 1140 Contract assets - current 1170 Accounts receivable, net 1200 Other receivables 130X Inventories 1410 Prepayments 11XX Total current assets Non-current assets 1517 Financial assets at fair value through other comprehensive income - non-current 1600 Property, plant and equipment 1755 Right-of-use assets 1780 Intangible assets 1840 Deferred income tax assets 1915 Prepayments for equipment 1920 Guarantee deposits paid 1980 Other financial assets - non- current 1990 Other non-current assets 15XX Total non-current assets 1XXX Total assets	6(1) 6(2) 6(17) 6(3) and 12 6(4) 6(5) 6(6)(8) and 7 6(7) 6(6) 6(24) 6(6) 6(1) and 8 6(6)				`34` `-` `-` `4` `-` `16` `1`
					`55`
					`1` `32` `6` `-` `5` `1` `-` `-` `-`
					`45`
					`100`

~7~

SCINOPHARM TAIWAN, LTD. AND SUBSIDIARIES CONSOLIDATED BALANCE SHEETS SEPTEMBER 30, 2025, DECEMBER 31, 2024 AND SEPTEMBER 30, 2024

(Expressed in thousands of New Taiwan dollars)

Liabilities and Equity	Notes	September 30, 2025 December 31, 2024 September 30, 2024 AMOUNT % AMOUNT % AMOUNT % `$` `139,477` `1` `$` `35,563` `-` `$` `35,704` `-` `2,107` `-` `1,225` `-` `-` `-` `75,940` `1` `119,396` `1` `157,755` `2` `-` `-` `1,211` `-` `1,603` `-` `112,017` `1` `80,959` `1` `126,966` `1` `314,652` `3` `498,191` `4` `341,918` `3` `21,627` `-` `11,499` `-` `11,803` `-` `23,797` `-` `19,638` `-` `18,286` `-` `689,617` `6` `767,682` `6` `694,035` `6` `1,625` `-` `1,304` `-` `395` `-` `612,627` `5` `620,342` `5` `622,136` `5` `11,436` `-` `23,614` `1` `23,489` `-` `3,698` `-` `3,992` `-` `4,343` `-` `629,386` `5` `649,252` `6` `650,363` `5` `1,319,003` `11` `1,416,934` `12` `1,344,398` `11` `7,907,392` `64` `7,907,392` `66` `7,907,392` `67` `1,294,689` `10` `1,294,689` `10` `1,294,689` `11` `817,709` `7` `783,817` `7` `783,817` `7` `126,177` `1` `185,856` `2` `185,856` `2` `324,925` `3` `480,227` `4` `383,318` `3` `522,054` `4 (` `126,177) (` `1)(` `115,166) (` `1)` `10,992,946` `89` `10,525,804` `88` `10,439,906` `89` `$` `12,311,949` `100` `$` `11,942,738` `100` `$` `11,784,304` `100`
		AMOUNT `$` `139,477` `2,107` `75,940` `-` `112,017` `314,652` `21,627` `23,797` `689,617` `1,625` `612,627` `11,436` `3,698` `629,386` `1,319,003` `7,907,392` `1,294,689` `817,709` `126,177` `324,925` `522,054` `10,992,946` `$` `12,311,949`
Current liabilities 2100 Short-term borrowings 2120 Financial liabilities at fair value through profit or loss - current 2130 Contract liabilities - current 2150 Notes payable 2170 Accounts payable 2200 Other payables 2230 Current income tax liabilities 2280 Lease liabilities - current 21XX Total current liabilities Non-current liabilities 2570 Deferred income tax liabilities 2580 Lease liabilities - non-current 2640 Net defined benefit liabilities - non-current 2645 Guarantee deposits received 25XX Total non-current liabilities 2XXX Total liabilities Equity attributable to owners of parent Share capital 3110 Common stock 3200 Capital surplus Retained earnings 3310 Legal reserve 3320 Special reserve 3350 Unappropriated earnings 3400 Other equity interest 3XXX Total equity Significant contingent liabilities and unrecognised contract commitments 3X2X Total liabilities and equity	6(9) 6(2) 6(17) 6(10) 6(24) 6(24) 6(11) 6(12) 6(13) 6(15) 6(16) 9

The accompanying notes are an integral part of these consolidated financial statements.

~8~

SCINOPHARM TAIWAN, LTD. AND SUBSIDIARIES CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME NINE MONTHS ENDED SEPTEMBER 30, 2025 AND 2024

(Expressed in thousands of New Taiwan dollars, except for earnings per share amount)

						Three months ended	Three months ended	Three months ended	September 30			Nine months ended	Nine months ended	Nine months ended	September 30
						2025			2024			2025			2024
	Items		Notes			AMOUNT	%		AMOUNT	%		AMOUNT	%		AMOUNT	%
4000	Operating revenue	6(17)			`$`	`721,495`	`100`	`$`	`724,223`	`100`	`$`	`2,155,381`	`100`	`$`	`2,369,808`	`100`
5000	Operating costs	6(4)(11)(22)(2
		3)		`(`		`505,661 ) (`	`70) (`		`445,235 ) (`	`61) (`		`1,392,015 ) (`	`64) (`		`1,446,744) (`	`61 )`
5900	Net operating margin					`215,834`	`30`		`278,988`	`39`		`763,366`	`36`		`923,064`	`39`
	Operating expenses	6(7)(11)(22)(2
		3), 7 and 12
6100	Selling expenses			`(`		`26,365 ) (`	`4) (`		`29,236 ) (`	`4) (`		`87,425 ) (`	`4) (`		`109,892) (`	`5 )`
6200	General and administrative
	expenses			`(`		`87,666 ) (`	`12) (`		`80,819 ) (`	`11) (`		`274,750 ) (`	`13) (`		`266,460) (`	`11 )`
6300	Research and development
	expenses			`(`		`121,397 ) (`	`17) (`		`135,971 ) (`	`19) (`		`302,108 ) (`	`14) (`		`290,211) (`	`12 )`
6450	Expected credit gain (loss)			`(`		`24 )`	`- (`		`1,126 )`	`-`		`1,790`	`- (`		`1,681)`	`-`
6000	Total operating expenses			`(`		`235,452 ) (`	`33) (`		`247,152 ) (`	`34) (`		`662,493 ) (`	`31) (`		`668,244) (`	`28 )`
6900	Operating profit			`(`		`19,618 ) (`	`3)`		`31,836`	`5`		`100,873`	`5`		`254,820`	`11`
	Non-operating income and
	expenses
7100	Interest income	6(18)				`12,009`	`2`		`15,064`	`2`		`41,125`	`2`		`45,238`	`2`
7010	Other income	6(5)(19)				`26,725`	`4`		`2,376`	`-`		`27,602`	`1`		`4,446`	`-`
7020	Other gains and losses	6(2)(8)(20)
		and	12			`2,770`	`- (`		`13,405 ) (`	`2) (`		`39,080 ) (`	`2)`		`722`	`-`
7050	Finance costs	6(7)(21)		`(`		`2,708 )`	`- (`		`1,934 )`	`- (`		`7,108 )`	`- (`		`6,001)`	`-`
7000	Total non-operating income
	and expenses					`38,796`	`6`		`2,101`	`-`		`22,539`	`1`		`44,405`	`2`
7900	Profit before income tax					`19,178`	`3`		`33,937`	`5`		`123,412`	`6`		`299,225`	`13`
7950	Income tax expense	6(24)		`(`		`3,732 ) (`	`1) (`		`6,834 ) (`	`1) (`		`27,742 ) (`	`1) (`		`57,217) (`	`3 )`
8200	Profit for the period				`$`	`15,446`	`2`	`$`	`27,103`	`4`	`$`	`95,670`	`5`	`$`	`242,008`	`10`
	Other comprehensive income
	(loss)
	Components of other
	comprehensive income (loss)
	that will not be reclassified to
	profit or loss
8316	Unrealised gain from equity	6(5)(16)
	instruments measured at fair
	value through other
	comprehensive income				`$`	`645,514`	`89`	`$`	`25,202`	`3`	`$`	`725,979`	`34`	`$`	`4,591`	`-`
	Components of other
	comprehensive income (loss)
	that will be reclassified to
	profit or loss
8361	Financial statements	6(16)
	translation differences of
	foreign operations					`63,527`	`9`		`15,637`	`2 (`		`77,748 ) (`	`4)`		`66,099`	`3`
8300	Total other comprehensive
	income for the period				`$`	`709,041`	`98`	`$`	`40,839`	`5`	`$`	`648,231`	`30`	`$`	`70,690`	`3`
8500	Total comprehensive income for
	the period				`$`	`724,487`	`100`	`$`	`67,942`	`9`	`$`	`743,901`	`35`	`$`	`312,698`	`13`
	Profit attributable to:
8610	Owners of the parent				`$`	`15,446`	`2`	`$`	`27,103`	`4`	`$`	`95,670`	`5`	`$`	`242,008`	`10`
	Comprehensive income
	attributable to:
8710	Owners of the parent				`$`	`724,487`	`100`	`$`	`67,942`	`9`	`$`	`743,901`	`35`	`$`	`312,698`	`13`
	Earnings per share (in dollars)	6(25)
9750	Basic				`$`		`0.02`	`$`		`0.03`	`$`		`0.12`	`$`		`0.31`
9850	Diluted				`$`		`0.02`	`$`		`0.03`	`$`		`0.12`	`$`		`0.31`

The accompanying notes are an integral part of these consolidated financial statements.

~9~

SCINOPHARM TAIWAN, LTD. AND SUBSIDIARIES CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY NINE MONTHS ENDED SEPTEMBER 30, 2025 AND 2024

(Expressed in thousands of New Taiwan dollars)

Notes			Equity a	Equity a	ttributable to owners o	f the parent
	Share capital - common stock	Capital reserve			Retained Earnings		Other EquityInterest
			Legal reserve		Special reserve	Unappropriated earnings	Financial statements translation differences of foreign operations	Unrealised (losses) gains from financial assets measured at fair value through other comprehensive income
6(5)(16) 6(15) 6(5)(16) 6(15)	`$` `7,907,392` `-` `-` `-` `-` `-` `-` `$` `7,907,392` `$` `7,907,392` `-` `-` `-` `-` `-` `-` `$` `7,907,392`	`$` `1,294,689` `-` `-` `-` `-` `-` `-` `$` `1,294,689` `$` `1,294,689` `-` `-` `-` `-` `-` `-` `$` `1,294,689`	`$` `755,145` `-` `-` `-` `28,672` `-` `-` `$` `783,817` `$` `783,817` `-` `-` `-` `33,892` `-` `-` `$` `817,709`	`$` `98,176` `-` `-` `-` `-` `87,680` `-` `$` `185,856` `$` `185,856` `-` `-` `-` `-` `-` `(` `59,679 )` `$` `126,177`		`$` `494,884` `242,008` `-` `242,008` `(` `28,672 )` `(` `87,680 )` `(` `237,222 )` `$` `383,318` `$` `480,227` `95,670` `-` `95,670` `(` `33,892 )` `(` `276,759 )` `59,679` `$` `324,925`	`($` `88,156` `)` `-` `66,099` `66,099` `-` `-` `-` `($` `22,057` `)` `($` `28,638` `)` `-` `(` `77,748` `)` `(` `77,748` `)` `-` `-` `-` `($` `106,386` `)`	`($` `97,700 )` `-` `4,591` `4,591` `-` `-` `-` `($` `93,109 )` `($` `97,539 )` `-` `725,979` `725,979` `-` `-` `-` `$` `628,440`	`$` `10,364,430` `242,008` `70,690` `312,698` `-` `-` `(` `237,222` `)` `$` `10,439,906` `$` `10,525,804` `95,670` `648,231` `743,901` `-` `(` `276,759` `)` `-` `$` `10,992,946`

The accompanying notes are an integral part of these consolidated financial statements.

~10~

SCINOPHARM TAIWAN, LTD. AND SUBSIDIARIES CONSOLIDATED STATEMENTS OF CASH FLOWS NINE MONTHS ENDED SEPTEMBER 30, 2025 AND 2024

(Expressed in thousands of New Taiwan dollars)

CASH FLOWS FROM OPERATING ACTIVITIES
Profit before tax
Adjustments
Adjustments to reconcile profit (loss)
Loss on valuation of financial assets and
liabilities at fair value through profit or loss
Expected credit (gain) loss

Loss on inventory market price decline

Depreciation of property, plant and equipment

Depreciation of right-of-use assets

(Gain) loss on disposal of property, plant and
equipment

Gain on reversal of impairment loss

Amortisation

Interest income

Dividend income

Interest expense

Changes in operating assets and liabilities
Changes in operating assets
Contract assets - current
Accounts receivable
Other receivables
Inventories
Prepayments
Changes in operating liabilities
Contract liabilities - current
Notes payable
Accounts payable
Other payables
Net defined benefit liabilities - non-current
Cash inflow generated from operations
Interest received
Dividends received
Interest paid
Income tax paid
Net cash flows from operating activities Notes
Nine months ended September 30
2025
2024
$
123,412 $
299,225
882
6,330
12
(
1,790 )
1,681
6(4)
44,982
40,049
6(6)(22)
354,809
345,001
6(7)(22)
15,288
12,928
6(20)
(
3 )
4,278
6(6)(8)(20)
(
63 )
-
6(22)
15,247
6,876
6(18)
(
41,125 ) (
45,238 )
6(5)(19)
(
25,615 )
-
6(21)
7,108
6,001
(
48,083 )
-
227,283
340,970
(
4,300 ) (
2,809 )
(
275,820 ) (
408,513 )
(
60,460 ) (
51,503 )
(
43,456 )
46,788
(
1,211 )
424
31,058
25,688
(
69,997 ) (
37,101 )
(
12,178 ) (
31,025 )
235,968
560,050
43,495
43,931
25,615
-
(
7,010 ) (
5,997 )
(
46,134 ) (
101,714 )
251,934
496,270

(Continued)

~11~

SCINOPHARM TAIWAN, LTD. AND SUBSIDIARIES CONSOLIDATED STATEMENTS OF CASH FLOWS NINE MONTHS ENDED SEPTEMBER 30, 2025 AND 2024

(Expressed in thousands of New Taiwan dollars)

CASH FLOWS FROM INVESTING ACTIVITIES
Acquisition of financial assets at fair value through
other comprehensive income - non-current
Cash paid for acquisition of property, plant and
equipment

Proceeds from disposal of property, plant and
equipment
Acquisition of intangible assets
Cash paid for prepayments for equipment

(Increase) decrease in guarantee deposits paid
Decrease in other financial assets - non-current
Increase in other assets - non-current
Net cash flows used in investing activities
CASH FLOWS FROM FINANCING ACTIVITIES
Increase in short-term borrowings

Decrease in short-term borrowings

Repayment of the principal portion of lease
liabilities

(Decrease) increase in guarantee deposits received

Payment of cash dividends

Net cash flows used in financing activities
Effect of foreign exchange rate changes
Net (decrease) increase in cash and cash equivalents
Cash and cash equivalents at beginning of period

Cash and cash equivalents at end of period Notes
Nine months ended September 30
2025
2024
($
1,156,000 ) $
-
6(26)
(
113,085 ) (
88,675 )
1,218
6,204
(
4,610 ) (
9,980 )
6(26)
(
96,196 ) (
141,979 )
(
701 )
8
1,670
-
(
1,737 )
-
(
1,369,441 ) (
234,422 )
6(27)
140,839
35,250
6(27)
(
34,175 ) (
33,084 )
6(27)
(
11,797 ) (
9,350 )
6(27)
(
181 )
2,974
6(15)
(
276,759 ) (
237,222 )
(
182,073 ) (
241,432 )
(
15,662 )
13,751
(
1,315,242 )
34,167
6(1)
4,165,987
3,941,524
6(1)
$
2,850,745 $
3,975,691

The accompanying notes are an integral part of these consolidated financial statements.

~12~

SCINOPHARM TAIWAN, LTD. AND SUBSIDIARIES NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS FOR THE NINE–MONTHS PERIODS ENDED SEPTEMBER 30, 2025 AND 2024 (Expressed in thousands of New Taiwan dollars, except as otherwise indicated)

1. HISTORY AND ORGANISATION

(1) ScinoPharm Taiwan, Ltd. (the “Company”) was incorporated as a company limited by shares under the provisions of the Company Act of the Republic of China (R.O.C.) on November 11, 1997. The Company and its subsidiaries (the “Group”) are primarily engaged in the manufacture of western medicines and other chemical materials, biological technology services, intellectual property rights, international trade and research, development, production, manufacture and sales of Active Pharmaceutical Ingredients (“API”), albumin medicines, oligonucleotide medicines, peptide medicines, injections and new small molecule drugs, as well as the provision of related consulting and technical services and international trade for the above products. In addition, the Company sells the chemical material which is reprocessed from the material recycled from the Company’s manufacturing process. For more information regarding the manufacturing and trading activities the Group are engaged in, refer to Note 4(3), “Basis of consolidation”.
(2) The common shares of the Company have been listed on the Taiwan Stock Exchange since September 2011.
(3) Uni-President Enterprises Corp., the Company’s ultimate parent company, holds 37.94% equity interest in the Company.
THE DATE OF AUTHORISATION FOR ISSUANCE OF THE CONSOLIDATED FINANCIAL

STATEMENTS AND PROCEDURES FOR AUTHORISATION

These consolidated financial statements were authorised for issuance by the Board of Directors on November 3, 2025.
APPLICATION OF NEW STANDARDS, AMENDMENTS AND INTERPRETATIONS
(1) Effect of the adoption of new issuances of or amendments to International Financial Reporting Standards (“IFRS[®] ”) Accounting Standards that came into effect as endorsed by the Financial Supervisory Commission (“FSC”)

New standards, interpretations and amendments endorsed by the FSC and became effective from 2025 are as follows:

Effective date by International Accounting New Standards, Interpretations and Amendments Standards Board (“IASB”) Amendments to IAS 21, ‘Lack of Exchangeability’ January 1, 2025

The above standards and interpretations have no significant impact to the Group’s financial condition and financial performance based on the Group’s assessment.

~13~

(2) Effect of new issuances of or amendments to IFRS Accounting Standards as endorsed by the FSC but

not yet adopted by the Group

New standards, interpretations and amendments endorsed by the FSC effective from 2026 are as follows:

==> picture [491 x 31] intentionally omitted <==

----- Start of picture text -----

Effective date by
New Standards, Interpretations and Amendments IASB
----- End of picture text -----

New Standards,Interpretations andAmendments	Effective date by IASB
Specific provisions of Amendments to IFRS 9 and IFRS 7, ‘Amendments	January 1, 2026
to the classification and measurement of financial instruments’
Amendments to IFRS 9 and IFRS 7, ‘Contracts referencing nature-	January 1, 2026
dependent electricity’
IFRS 17, ‘Insurance contracts’	January 1, 2023
Amendments to IFRS 17, ‘Insurance contracts’	January 1, 2023
Amendment to IFRS 17, ‘Initial application of IFRS 17 and IFRS 9 –	January 1, 2023
comparative information’
Annual Improvements to IFRS Accounting Standards – Volume 11	January 1, 2026

The above standards and interpretations have no significant impact to the Group’s financial condition and financial performance based on the Group’s assessment.

(3) IFRS Accounting Standards issued by IASB but not yet endorsed by the FSC

New standards, interpretations and amendments issued by IASB but not yet included in the IFRS Accounting Standards as endorsed by the FSC are as follows:

Accounting Standards as endorsed by the FSC are as follows:
New Standards,InterpretationsandAmendments Amendments to IFRS 10 and IAS 28, ‘Sale or contribution of assets between an investor and its associate or joint venture’ IFRS 18, ‘Presentation and disclosure in financial statements’ IFRS 19, ‘Subsidiaries without public accountability: disclosures’	Effective date by IASB
	To be determined by IASB
	January 1, 2027 (Note)
	January 1, 2027

Note ： The FSC has announced in a press release on September 25, 2025 that public companies will apply IFRS 18 starting from the fiscal year 2028. Additionally, entities can choose to adopt IFRS 18 earlier based on their requirements after the FSC endorses IFRS 18.

Except for the following, the above standards and interpretations have no significant impact to the Group’s financial condition and financial performance based on the Group’s assessment. IFRS 18, ‘Presentation and disclosure in financial statements’

IFRS 18, ‘Presentation and disclosure in financial statements’ replaces IAS 1. The standard introduces

a defined structure of the statement of profit or loss, disclosure requirements related to managementdefined performance measures, and enhanced principles on aggregation and disaggregation which apply to the primary financial statements and notes.

~14~

4. SUMMARY OF MATERIAL ACCOUNTING POLICIES

Except for the compliance statement, basis of preparation, basis of consolidation and applicable policies of the interim financial statements as set out below, the other principal accounting policies are in agreement with Note 4 of the consolidated financial statements for the year ended December 31, 2024. These policies have been consistently applied to all the periods presented, unless otherwise stated.

(1) Compliance statement

A. The consolidated financial statements of the Group have been prepared in accordance with the “Regulations Governing the Preparation of Financial Reports by Securities Issuers”, and IAS 34, ``` Interim Financial Reporting’ that came into effect as endorsed by the FSC.
B. The consolidated financial statements should be read together with the consolidated financial statements for the year ended December 31, 2024.
(2) Basis of preparation
A. Except for the following items, these consolidated financial statements have been prepared under the historical cost convention:
- (a) Financial assets and financial liabilities (including derivative instruments) at fair value through profit or loss.
- (b) Financial assets at fair value through other comprehensive income.
- (c) Defined benefit liabilities recognised based on the net amount of pension fund assets less present value of defined benefit obligation.
B. The preparation of financial statements in conformity with International Financial Reporting Standards, International Accounting Standards, IFRIC[®] Interpretations and SIC[®] Interpretations that came into effect as endorsed by the FSC (collectively referred herein as the “IFRSs”) requires that use of certain critical accounting estimates. It also requires management to exercise its judgement in the process of applying the Group’s accounting policies. The areas involving a higher degree of judgement or complexity, or areas where assumptions and estimates are significant to the consolidated financial statements are disclosed in Note 5.
(3) Basis of consolidation
A. Basis for preparation of consolidated financial statements: The basis for preparation of these consolidated financial statements is consistent with those for the preparation of consolidated financial statements for the year ended December 31, 2024.
B. Subsidiaries included in the consolidated financial statements:

Name of Investors	Name of Subsidiaries	Business September 30, December 31, September 30, Activities 2025 2024 2024 Professional investment 100.00 100.00 100.00 Company Percentage owned by the	Note
ScinoPharm Taiwan, Ltd.	SPT International, Ltd.		`－`

~15~

==> picture [471 x 59] intentionally omitted <==

----- Start of picture text -----

Percentage owned by the
Company
Name of Name of Business September 30, December 31, September 30,
Investors Subsidiaries Activities 2025 2024 2024 Note
----- End of picture text -----

Investors	Subsidiaries	Activities	2025	2024	2024	Note
ScinoPharm	ScinoPharm	Professional	100.00	100.00	100.00	(Note)
Taiwan, Ltd.	Singapore	investment
	Pte Ltd.
SPT	SciAnda	Research,	100.00	100.00	100.00	`－`
International,	(Changshu)	development
Ltd.	Pharmaceuticals,	and manufacture
	Ltd.	of API and new
		drugs, sales of
		self-produced
		products, etc.
SPT	SciAnda	Import, export	100.00	100.00	100.00	(Note)
International,	Shanghai	and sales of
Ltd.	Biochemical	API and
	Technology,	intermediates,
	Ltd.	etc.

Note : The financial statements of the entity as of and for the nine-month periods ended September

30, 2025 and 2024 were not reviewed by independent auditors as the entity did not meet the definition of a significant subsidiary.

C. Subsidiaries not included in the consolidated financial statements: None.
D. Adjustments for subsidiaries with different balance sheet dates: None.
E. Significant restrictions: None.
F. Subsidiaries that have non-controlling interests that are material to the Group: None.

(4) Employee benefits

Defined benefit plans

Pension cost for the interim period is calculated on a year-to-date basis by using the pension cost rate derived from the actuarial valuation at the end of the prior financial year, adjusted for significant market fluctuations since that time and for significant curtailments, settlements, or other significant one-off events. Also, the related information is disclosed accordingly.

(5) Income tax

The interim period income tax expense is recognised based on the estimated average annual effective income tax rate expected for the full financial year applied to the pretax income of the interim period, and the related information is disclosed accordingly.

5. CRITICAL ACCOUNTING JUDGEMENTS, ESTIMATES AND KEY SOURCES OF ASSUMPTION UNCERTAINTY

There have been no significant changes during the period. Refer to Note 5 of the consolidated financial statements for the year ended December 31, 2024.

~16~

6. DETAILS OF SIGNIFICANT ACCOUNTS

(1) CASH AND CASH EQUIVALENTS

September30,2025 Cash: Cash on hand 119 $ Checking accounts and demand deposits 102,126 102,245 Cash equivalents: Time deposits 2,648,500 Bills under repurchase agreements 100,000 2,748,500 2,850,745 $	December31,2024 September30,2024 129 $ 128 $ 167,117 237,063 167,246 237,191 3,833,741 3,648,500 165,000 90,000 3,998,741 3,738,500 4,165,987 $ 3,975,691 $

A. The Group transacts with a variety of financial institutions all with high credit quality to disperse credit risk, so it expects that the probability of counterparty default is remote.
B. Details of the Group’s time deposits pledged to others as collateral (listed as “Other financial assets - non-current”) as of September 30, 2025, December 31, 2024, and September 30, 2024 are provided in Note 8, “Pledged assets”.

(2) FINANCIAL ASSETS AND LIABILITIES AT FAIR VALUE THROUGH PROFIT OR LOSS

Items Current items: Financial (liabilities) assets mandatorily measured at fair value through profit or loss Derivatives ( Non-current items: Financial assets mandatorily measured at fair value through profit or loss Unlisted stocks Valuation adjustment (	September30,2025 2,107) $ ( 4,620 $ 4,620) ( - $	December31,2024 1,225) $ 4,620 $ 4,620) ( - $	September30,2024 1,974 $ 4,620 $ 4,620) - $

A. The Group recognised net (loss) gain of ($9,939), $1,506, $2,884 and ($21,178) on financial assets and liabilities at fair value through profit or loss (listed as “Other gains and losses”) for the threemonth and nine-month periods ended September 30, 2025 and 2024, respectively.

~17~

B. The Group entered into contracts relating to derivative financial assets and liabilities which were not accounted for under hedge accounting. The information is listed below (Units in thousands of currencies indicated):

==> picture [472 x 165] intentionally omitted <==

----- Start of picture text -----

September 30, 2025
Items Contract amount Contract period
Forward foreign exchange contracts USD 7,200 7.2025~11.2025
December 31, 2024
Items Contract amount Contract period
Forward foreign exchange contracts USD 7,830 11.2024~2.2025
September 30, 2024
Items Contract amount Contract period
Forward foreign exchange contracts USD 6,360 8.2024~11.2024
----- End of picture text -----

The Group entered into forward foreign exchange contracts to hedge exchange rate risk of operating activities. However, these forward foreign exchange contracts are not accounted for under hedge accounting.

C. The Group has no financial assets at fair value through profit or loss pledged to others as of September 30, 2025, December 31, 2024, and September 30, 2024.

(3) ACCOUNTS RECEIVABLE, NET

A. The ageing analysis of accounts receivable is as follows: September30,2025 December31,2024 Accounts receivable 378,840 $ 606,123 $ Less: Loss allowance 114) ( 1,904) ( ( 378,726 $ 604,219 $ September30,2025 December31,2024 Not past due 309,450 $ 509,007 $ Less than 30 days 43,949 94,992 Between 31 to 90 days 25,350 308 Between 91 to 180 days 91 - Over 181 days - 1,816 378,840 $ 606,123 $	September30,2024 447,482 $ 1,917) 445,565 $ September30,2024 332,958 $ 81,468 30,987 316 1,753 447,482 $

The above ageing analysis is based on past due date.

B. As of September 30, 2025, December 31, 2024, and September 30, 2024, accounts receivable arose from contracts with customers. As of January 1, 2024, the balance of receivables from contracts with customers amounted to $788,452.
C. As of September 30, 2025, December 31, 2024, and September 30, 2024, the Group does not hold any collateral as security.

~18~

D. As of September 30, 2025, December 31, 2024, and September 30, 2024, without taking into account any collateral held or other credit enhancements, the maximum exposure to credit risk in respect of the amount that best represents the Group’s notes and accounts receivable was the book value amount.
E. Information relating to credit risk of accounts receivable is provided in Note 12(2), “Financial instruments”.

(4) INVENTORIES

instruments”. NVENTORIES
Raw materials Supplies Work in process Finished goods Raw materials Supplies Work in process Finished goods Raw materials Supplies Work in process Finished goods		September30,2025
	Allowance for Cost marketprice decline 348,503 $ 61,673) ($ 92,812 3,571) ( 632,807 105,264) ( 1,287,036 286,193) ( 2,361,158 $ 456,701) ($ Allowance for Cost market price decline 375,907 $ 64,953) ($ 51,867 4,639) ( 658,527 85,105) ( 1,002,857 261,454) ( 2,089,158 $ 416,151) ($ September 30, 2024 December31,2024		Bookvalue
			286,830 $ 89,241 527,543 1,000,843
			1,904,457 $
			Bookvalue
			310,954 $ 47,228 573,422 741,403
			1,673,007 $

	Allowance for Cost marketprice decline 380,299 $ 71,014) ($ 55,655 4,645) ( 645,705 101,430) ( 1,241,463 269,434) ( 2,323,122 $ 446,523) ($		Bookvalue
			309,285 $ 51,010 544,275 972,029
			1,876,599 $

~19~

The cost of inventories recognised as expense for the period:

For the three-month periods ended September 30,

Cost of goods sold Loss on physical inventory Under applied manufacturing overhead Loss on inventory market price decline Revenue from sale of scraps Cost of goods sold Loss on scrap inventory Loss on physical inventory Under applied manufacturing overhead Loss on inventory market price decline Revenue from sale of scraps	2025 2024 313,383 $ 292,118 $ 144 156 127,704 114,903 17,307 17,958 512) ( 462) ( 458,026 $ 424,673 $ 2025 2024 926,396 $ 1,057,298 $ 3,324 - 380 559 345,974 316,862 44,982 40,049 1,551) ( 1,375) ( 1,319,505 $ 1,413,393 $ For thenine-monthperiods ended September30,

(5) FINANCIAL ASSETS AT FAIR VALUE THROUGH OTHER COMPREHENSIVE INCOME - NON-CURRENT

Items Equity instruments Emerging stocks Unlisted stocks Valuation adjustment	September30,2025 1,156,000 $ 167,673 1,323,673 628,440 ( 1,952,113 $	December31,2024 - $ 167,673 167,673 97,539) ( 70,134 $	September30,2024 - $ 167,673 167,673 93,109) 74,564 $

A. The Group has elected to classify investments that are considered to be strategic investments as financial assets at fair value through other comprehensive income. The fair value of such investments is the book value as of September 30, 2025, December 31, 2024, and September 30, 2024.

2024.	2024.
B. Amounts recognised in other comprehensive income in		relation to the financial		assets at fair value
through other comprehensive income are listed below:
Equity instruments at fair value through	For the	three-monthperiods ended September30,
othercomprehensiveincome		2025		2024
Fair value change recognised in other
comprehensive income	$	645,514	$	25,202
Dividend income recognised in profit or loss	$	25,615	$	-

~20~

==> picture [468 x 80] intentionally omitted <==

----- Start of picture text -----

Equity instruments at fair value through For the nine-month periods ended September 30,
other comprehensive income 2025 2024
Fair value change recognised in other
comprehensive income $ 725,979 $ 4,591
Dividend income recognised in profit or loss $ 25,615 $ -
----- End of picture text -----

C. The Group has no financial assets at fair value through other comprehensive income pledged to others as of September 30, 2025, December 31, 2024, and September 30, 2024.

~21~

(6) PROPERTY, PLANT AND EQUIPMENT

																		Construction in
																		progress and
																		equipment before
					Machinery and			Transportation				Office			Other			acceptance
January 1, 2025			Buildings			equipment			equipment			equipment			equipment			inspection			Total
Cost		$	4,309,016		$	6,194,785		$	29,299		$	254,278		$	173,026		$	194,044		$	11,154,448
Accumulated depreciation	(		2,074,839)	(		4,976,305)	(		22,930)	(		198,727)	(		138,624)			-	(		7,411,425)
Accumulated impairment			-	(		4,134)			-			-			-			-	(		4,134)
		$	2,234,177		$	1,214,346		$	6,369		$	55,551		$	34,402		$	194,044		$	3,738,889
For the nine-month period ended
September 30, 2025
At January 1		$	2,234,177		$	1,214,346		$	6,369		$	55,551		$	34,402		$	194,044		$	3,738,889
Additions			-			703			-			24			-			46,685			47,412
Reclassified from prepayments
for equipment			-			-			-			-			-			59,487			59,487
Reclassified upon completion			8,097			188,253			142			29,706			2,303	(		228,501)			-
Reclassified to intangible assets			-			-			-			-			-	(		1,278)	(		1,278)
Reclassified to other non-current assets－
others			-			-			-			-			-	(		5,755)	(		5,755)
Depreciation charge	(		141,141)	(		193,196)	(		1,469)	(		16,249)	(		2,754)			-	(		354,809)
Disposals`－`Cost	(		1,684)	(		36,235)			-	(		20,063)	(		680)			-	(		58,662)
' `－`Accumulated depreciation			778			36,041			-			20,016			612			-			57,447
Reversal of impairment loss			-			63			-			-			-			-			63
Net currency exchange differences	(		33,912)	(		17,151)	(		165)	(		830)	(		1,321)	(		6,087)	(		59,466)
At September 30		$	2,066,315		$	1,192,824		$	4,877		$	68,155		$	32,562		$	58,595		$	3,423,328
September 30, 2025
Cost		$	4,263,020		$	6,305,266		$	29,046		$	260,034		$	166,756		$	58,595		$	11,082,717
Accumulated depreciation	(		2,196,705)	(		5,108,371)	(		24,169)	(		191,879)	(		134,194)			-	(		7,655,318)
Accumulated impairment			-	(		4,071)			-			-			-			-	(		4,071)
		$	2,066,315		$	1,192,824		$	4,877		$	68,155		$	32,562		$	58,595		$	3,423,328

~22~

																		Construction in
																		progress and
																		equipment before
					Machinery and			Transportation				Office			Other			acceptance
January 1, 2024			Buildings			equipment			equipment			equipment			equipment			inspection			Total
Cost		$	4,249,075		$	5,998,911		$	26,907		$	244,141		$	165,103		$	77,715		$	10,761,852
Accumulated depreciation	(		1,875,104)	(		4,772,711)	(		21,402)	(		195,193)	(		131,732)			-	(		6,996,142)
Accumulated impairment			-	(		3,014)			-			-			-			-	(		3,014)
		$	2,373,971		$	1,223,186		$	5,505		$	48,948		$	33,371		$	77,715		$	3,762,696
For the nine-month period ended
September 30, 2024
At January 1		$	2,373,971		$	1,223,186		$	5,505		$	48,948		$	33,371		$	77,715		$	3,762,696
Additions			-			136			-			18			-			45,976			46,130
Reclassified from prepayments
for equipment			-			-			-			-			-			201,670			201,670
Reclassified upon completion			25,829			184,834			1,154			14,164			2,967	(		228,948)			-
Depreciation charge	(		141,562)	(		186,687)	(		1,277)	(		12,938)	(		2,537)			-	(		345,001)
Disposals`－`Cost	(		9,300)	(		40,042)	(		351)	(		15,224)	(		1,069)			-	(		65,986)
' `－`Accumulated depreciation			2,046			36,907			351			15,202			998			-			55,504
Net currency exchange differences			30,666			13,817			126			705			1,113			927			47,354
At September 30		$	2,281,650		$	1,232,151		$	5,508		$	50,875		$	34,843		$	97,340		$	3,702,367
September 30, 2024
Cost		$	4,310,459		$	6,177,089		$	27,990		$	246,216		$	173,640		$	97,340		$	11,032,734
Accumulated depreciation	(		2,028,809)	(		4,941,924)	(		22,482)	(		195,341)	(		138,797)			-	(		7,327,353)
Accumulated impairment			-	(		3,014)			-			-			-			-	(		3,014)
		$	2,281,650		$	1,232,151		$	5,508		$	50,875		$	34,843		$	97,340		$	3,702,367

~23~

A. The Group has not capitalised borrowing costs as part of property, plant and equipment for the three-month and nine-month periods ended September 30, 2025 and 2024.
B. The Group’s property, plant and equipment were owner-occupied for the nine-month periods ended September 30, 2025 and 2024.
C. As of September 30, 2025, December 31, 2024, and September 30, 2024, the Group has not pledged any property, plant and equipment as collateral.
－
(7) LEASING ARRANGEMENTS LESSEE
A. The Group leases land and buildings and structures. Rental contracts are typically made for periods of 50 (including the option to extend the leases) and 2 years. Lease terms are negotiated on an individual basis and contain a wide range of different terms and conditions, with no restrictions other than the use of the subject matter of the lease in accordance with relevant laws and regulations.
B. Short-term leases with a lease term of 12 months or less pertain to office premises and low-value assets pertain to computers.
C. The carrying amount of right-of-use assets and the depreciation charge are as follows:

Land
Buildings and structures
Land
Buildings and structures
Land
Buildings and structures

September30,2025
December31,2024
September30,2024
Carryingamount
Carryingamount
Carryingamount
669,294
$ 684,290
$ 688,527
$ 7,177
2,345

-
676,471
$ 686,635
$ 688,527
$ 2025
2024
Depreciation charge
Depreciationcharge
3,945
$ 3,980
$ 1,365
335
5,310
$ 4,315
$ 2025
2024
Depreciationcharge
Depreciationcharge
11,879
$ 11,921
$ 3,409
1,007
15,288
$ 12,928
$ For thenine-monthperiods ended September30,
For thethree-monthperiods ended September30,

D. For the three-month and nine-month periods ended September 30, 2025 and 2024, the Group’s －－－
additions of right-of-use assets were $ , $ , $8,241 and $ , respectively; the remeasurements －－－
of right-of-use assets were $ , $ , $ and $61,985, respectively.

~24~

E. The information on income and expense accounts relating to lease contracts is as follows:

	For thethree-monthperiods ended September30,	For thethree-monthperiods ended September30,	For thethree-monthperiods ended September30,	For thethree-monthperiods ended September30,
		2025		2024
Items affecting profit or loss
Interest expense on lease liabilities	$	1,820	$	1,815
Expense on short-term lease contracts		241		220
Expense on leases of low-value assets		876		1,068
	For thenine-monthperiods ended September30,
		2025		2024
Items affecting profit or loss
Interest expense on lease liabilities	$	5,476	$	5,473
Expense on short-term lease contracts		764		461
Expense on leases of low-value assets		2,343		3,143

F. For the nine-month periods ended September 30, 2025 and 2024, the Group’s total cash outflow for leases were $20,380 and $18,427, respectively.

(8) IMPAIRMENT OF NON-FINANCIAL ASSETS

A. For the three-month and nine-month periods ended September 30, 2025 and 2024, the Group －－－
recognised the reversal of impairment loss amounting to $ , $ , $63 and $ , respectively (listed as “Other gains and losses”) as some of the idle machineries were disposed. For details of accumulated impairment, refer to Note 6(6), “ Property, plant and equipment”.
B. The reversal of impairment loss reported by operating segments is as follows:

Segment ScinoPharm Taiwan, Ltd.	Recognised in other Recognised in other Recognised in comprehensive Recognised in comprehensive profitor loss income profitor loss income 63 $ - $ - $ - $ 2025 2024 For thenine-monthperiods ended September30,
	Recognised in other Recognised in comprehensive profitor loss income 63 $ - $ 2025

There was no such situation for the three-month periods ended September 30, 2025 and 2024.

~25~

(9) SHORT-TERM BORROWINGS

==> picture [485 x 182] intentionally omitted <==

----- Start of picture text -----

Type of borrowings September 30, 2025 Interest rate Collateral
Bank loans
Unsecured loans $ 139,477 2.60%～2.80% None
Type of borrowings December 31, 2024 Interest rate Collateral
Bank loans
Unsecured loans $ 35,563 2.90%～3.00% None
Type of borrowings September 30, 2024 Interest rate Collateral
Bank loans
Unsecured loans $ 35,704 2.90%～3.00% None
----- End of picture text -----

Refer to Note 6(21), “ Finance costs” for interest expense recognised in profit or loss for the threemonth and nine-month periods ended September 30, 2025 and 2024.

(10) OTHER PAYABLES

OTHER PAYABLES
September 30, 2025 Accrued salaries and bonuses 92,680 $ Payables on equipment 40,582 Accrued employees’ compensation and directors’ remuneration 13,868 Others 167,522 314,652 $	December31,2024 September 30, 2024 96,725 $ 96,100 $ 154,222 32,035 46,723 33,788 200,521 179,995 498,191 $ 341,918 $
		96,100 $ 32,035 33,788 179,995
		341,918 $

(11) PENSIONS

A. The Company has set up a defined benefit pension plan in accordance with the Labor Standards Law, which applies to all regular employees’ service years prior to the enforcement of the Labor Pension Act (the “Act”) on July 1, 2005 and service years thereafter of employees who chose to continue to be covered under the pension scheme of the Labor Standards Law after the enforcement of the Act. In accordance with the Company's retirement plan, an employee may retire when the employee either (i) attains the age of 55 with 15 years of service, (ii) has more than 25 years of service, (iii) has reached the age of 65, or (iv) is incapacitated to work (compulsory retirement). The employees earn two units for each year of service for the first 15 years, and one unit for each additional year thereafter up to a maximum of 45 units. Any fraction of a year equal to or more than six months shall be counted as one year of service, and any fraction of a year less than six months shall be counted as half a year. According to the provisions, employees who retired due to their duties shall get additional 20%. Pension payments are based on the number of units earned and the average salary of the last six months prior to retirement. Calculation of average salary is in accordance with the Labor Standards Law of the R.O.C. The

~26~

Company contributes monthly an amount equal to 2% of the employees' monthly salaries and wages to the retirement fund deposited with Bank of Taiwan under the name of the independent retirement fund committee. Also, the Company would assess the balance in the aforementioned labor pension reserve account by December 31, every year. If the account balance is not enough to pay the pension calculated by the aforementioned method to the employees expected to qualify for retirement in the following year, the Company will make contribution for the deficit by end of March next year.

(a) The pension costs under the aforementioned defined benefit pension plan of the Company for the three-month and nine-month periods ended September 30, 2025 and 2024 were $287, $272, $860 and $817, respectively.
(b) Expected contributions to the defined benefit pension plan of the Company for 2025 amount to $2,762.
B. As a result of the enforcement of the Act, the Company set up a defined contribution pension plan which took effect on July 1, 2005. The local employees are eligible for the defined contribution plan. For employees who choose to be covered under the pension scheme of the Act, the Company contributes monthly an amount of not less than 6% of the employees’ monthly salaries and wages to the employees’ individual pension accounts at the Bureau of Labor Insurance. Pensions are paid by monthly installments or in lump sum based on the accumulated balances of the employees’ individual pension accounts. The subsidiaries in Mainland China (SciAnda (Changshu) Pharmaceuticals, Ltd., and SciAnda Shanghai Biochemical Technology, Ltd.) are subject to a government sponsored defined contribution plan. In accordance with the related Laws of the People’s Republic of China, the subsidiaries in Mainland China contribute monthly 18% of the employees’ monthly salaries and wages to an independent fund administered by the government. Other than the monthly contributions, these subsidiaries do not have further obligations. The other subsidiaries, SPT International, Ltd. and ScinoPharm Singapore Pte Ltd., had no employees. For the three-month and nine-month periods ended September 30, 2025 and 2024, the pension costs recognised under the aforementioned defined contribution pension plans were $10,775, $10,410, $32,421 and $31,047, respectively.

(12) SHARE CAPITAL

A. Movements in the number of the Company’s ordinary shares outstanding are as follows (in thousands of shares):

thousands of shares):
At January 1 and September 30	For thenine-monthperiods ended September30,
	2025 790,739	2024
		790,739

B. As of September 30, 2025, the Company’s authorised capital was $10,000,000, and the paid-in capital was $7,907,392 (790,739 thousand shares) with a par value of $10 (in dollars) per share. All proceeds from shares issued have been collected.

~27~

(13) CAPITAL RESERVES

A. Pursuant to the R.O.C. Company Act, capital reserve arising from paid-in capital in excess of par value on issuance of common stocks and donations shall be exclusively used to cover accumulated deficit or, distribute cash or stocks in proportion to their share ownership, provided that the Company has no accumulated deficit. Further, the R.O.C. Securities and Exchange Act requires that the capital reserve to be capitalised mentioned above should not exceed 10% of the paid-in capital each year. Capital reserve should not be used to cover accumulated deficit unless the legal reserve is insufficient.
B. Movements on the Company’s capital reserve are as follows:

At January 1 Employee stock options forfeited - Company At September 30 At January 1 Employee stock options forfeited - Company At September 30	Share premium Stock options Total 1,265,818 $ 28,871 $ 1,294,689 $ 2,494 2,494) ( - 1,268,312 $ 26,377 $ 1,294,689 $ For thenine-monthperiod ended September30,2025 Share premium Stockoptions Total 1,265,336 $ 29,353 $ 1,294,689 $ 482 482) ( - 1,265,818 $ 28,871 $ 1,294,689 $ For thenine-monthperiod ended September30,2024	Share premium Stock options Total 1,265,818 $ 28,871 $ 1,294,689 $ 2,494 2,494) ( - 1,268,312 $ 26,377 $ 1,294,689 $ For thenine-monthperiod ended September30,2025 Share premium Stockoptions Total 1,265,336 $ 29,353 $ 1,294,689 $ 482 482) ( - 1,265,818 $ 28,871 $ 1,294,689 $ For thenine-monthperiod ended September30,2024
		1,294,689 $ -
		1,294,689 $

(14) SHARE-BASED PAYMENT – EMPLOYEES’ COMPENSATION

A. The Company issued 1.5 million units and 1.5 million units of employee stock options on November 6, 2015 and October 14, 2016, respectively (the ‘Grant Date’). The exercise price of the options was set at $41.65 (in dollars) and $40.55 (in dollars), respectively, which was based on the closing market price of the Company’s common shares on the Grant Dates. Each option gives the holder the right to purchase one share of the Company’s common stocks. The exercise price is subject to further adjustments when there is a change in the number of shares of the Company’s common stocks, the cash dividend of the common stocks is more than 1.5% of the current price per share or there is a decrease in common stocks caused by capital reduction not due to the retirement of treasury share after the Grant Date. Contract period of the employee stock option plans is 10 years, and options are exercisable in 2 years after the Grant Date.

~28~

B. Details of the share-based payment arrangements are as follows:

Options outstanding at beginning of the period Options forfeited ( Options outstanding at end of the period Options exercisable at end of the period Options outstanding at beginning of the period Options forfeited ( Options outstanding at end of the period Options exercisable at end of the period	Weighted-average Number of options exercise price (in thousand units) (indollars) 1,128 36.07 $ 186) 36.11 942 35.32 942 35.32 For thenine-monthperiod ended September30,2025 For thenine-monthperiod ended September30,2024
	Weighted-average Number of options exercise price (in thousand units) (in dollars) 1,164 36.07 $ 36) 36.13 1,128 36.07 1,128 36.07

C. The expiry date, exercisable shares and exercise prices of the employee stock options at balance sheet date are as follows:

		September30,	September30,	2025	December31,	December31,	2024
			Exercise price			Exercise price
		No. of stocks	(in dollars)		No. of stocks	(in dollars)
Grantdate	Expiry date	(unit in thousands)		(Note)	(unit in thousands)		(Note)
11.6.2015	11.5.2025	445	$	35.06	515	$	35.80
10.14.2016	10.13.2026	497		35.55	613		36.30
					September30,		2024
						Exercise price
					No. of stocks	(in dollars)
Grantdate	Expiry date				(unit in thousands)		(Note)
11.6.2015	11.5.2025				515	$	35.80
10.14.2016	10.13.2026				613		36.30
Note: Exercise price is adjusted according to a specific formula.

~29~

D. The fair value of the Group’s employee stock options on Grant Date was evaluated using the combination of Hull & White and the Ritchken trinomial option valuation model. Related information is as follows:

information is	as follows:
Type of arrangement	Grantdate 11.6.2015 10.14.2016	Stock price (indollars) 41.65 $ 40.55	Exercise price (indollars) 41.65 $ 40.55	Price volatility	Option life	Expected dividends	Interest rate 1.2936% 0.9223%	Fair value per unit (indollars)
Employee stock options Employee stock options				37.63% (Note) 37.20% (Note)	10 years 10 years	1.5% 1.5%		13.799 $ 13.171

Note: According to daily returns of the Company’s stock for the previous year, the annualised volatility were 37.63% and 37.20%, respectively.

(15) RETAINED EARNINGS

A. Pursuant to the amended R.O.C. Company Act, the current year’s after-tax earnings should be used initially to cover any accumulated deficit; thereafter 10% of the remaining earnings should be set aside as legal reserve until the balance of legal reserve is equal to that of paid-in capital. The legal reserve shall be exclusively used to cover accumulated deficit, to issue new stocks, or to distribute cash to shareholders in proportion to their share ownership. The use of legal reserve for the issuance of stocks or cash dividends to shareholders in proportion to their share ownership is permitted provided that the distribution of the reserve is limited to the portion in excess of 25% of the Company’s paid-in capital.
B. According to the Articles of Incorporation of the Company, since the Company is in a changeable industry environment and the life cycle of the Company is in a stable growth, the appropriation of earnings should consider fund requirements and capital budget to decide how much earnings will be kept or distributed and how much cash dividends will be distributed. According to the Company’s Articles of Incorporation, 10% of the annual net income, except for offsetting any loss of prior years and paying all taxes and dues according to laws, after adding items other than net profit after taxes for the year into undistributed surplus earnings of current year, 10% of the remaining shall be set aside as legal reserve. The remaining net income and the unappropriated retained earnings from prior years can be distributed in accordance with a resolution passed during a meeting of the Board of Directors and approved at the stockholders’ meeting. Of the amount to be distributed by the Company, stockholders’ dividends shall comprise 50% to 100% of the unappropriated retained earnings, and the percentage of cash dividends shall not be less than 30% of dividends distributed.
C. In accordance with the regulations, the Company shall set aside special reserve from the debit balance on other equity items at the balance sheet date before distributing earnings. When debit balance on other equity items is reversed subsequently, the reversed amount could be included in the distributable earnings. The amounts previously set aside by the Company as special reserve on initial application of IFRSs in accordance with Order No. Jin-Guan-Zheng-Fa-Zi Letter No.

~30~

1010012865, dated April 6, 2012, shall be reversed proportionately when the relevant assets are used, disposed of or reclassified subsequently. As of September 30, 2025, the amount of special reserve on initial application of IFRSs provided in accordance with the order from Financial Supervisory Committee was $22,829.

D. The Company recognised cash dividends distributed to owners amounting to $237,222 ($0.3 (in dollars) per share) for the year ended December 31, 2024. On May 28, 2025, the stockholders approved the distribution of cash dividends of $276,759 ($0.35 (in dollars) per share) from 2024 earnings.

(16) OTHER EQUITY ITEMS

earnings. OTHER EQUITY ITEMS
			For thenine-month		period ended September			30,2025
					Unrealised loss
		Currencytranslation			onvaluation			Total
At January 1	($		28,638)	($	97,539)	($		126,177)
Revaluation			-		725,979			725,979
Currency translation differences
- Group	(		77,748)		-	(		77,748)
At September 30	($		106,386)	$	628,440		$	522,054
			For thenine-month		period ended September			30,2024
					Unrealised loss
		Currencytranslation			onvaluation			Total
At January 1	($		88,156)	($	97,700)	($		185,856)
Revaluation			-		4,591			4,591
Currency translation differences
- Group			66,099		-			66,099
At September 30	($		22,057)	($	93,109)	($		115,166)

(17) OPERATING REVENUE

A. Disaggregation of revenue from contracts with customers

The Group derives revenue from the transfer of goods at a point in time and the rendering of services over time in the following major product lines:

For the three-month period ended September30,2025 Timing of revenue recognition: At a point in time Over time	API Income 576,844 $ - 576,844 $	Injection Product Income 51,210 $ - 51,210 $	Technical Service Income - $ 88,688 88,688 $	Other Operating Income 4,753 $ - 4,753 $	Total
					632,807 $ 88,688
					721,495 $

~31~

==> picture [460 x 392] intentionally omitted <==

----- Start of picture text -----

For the three-month Injection Technical Other
period ended API Product Service Operating
September 30, 2024 Income Income Income Income Total
Timing of revenue
recognition:
At a point in time $ 577,488 $ 20,512 $ - $ 49 $ 598,049
Over time - - 126,174 - 126,174
$ 577,488 $ 20,512 $ 126,174 $ 49 $ 724,223
For the nine-month Injection Technical Other
period ended API Product Service Operating
September 30, 2025 Income Income Income Income Total
Timing of revenue
recognition:
-
At a point in time $ 1,831,894 $ 122,175 $ $ 30,031 $ 1,984,100
Over time - - 171,281 - 171,281
$ 1,831,894 $ 122,175 $ 171,281 $ 30,031 $ 2,155,381
For the nine-month Injection Technical Other
period ended API Product Service Operating
September 30, 2024 Income Income Income Income Total
Timing of revenue
recognition:
-
At a point in time $ 2,087,535 $ 58,991 $ $ 35,168 $ 2,181,694
Over time - - 188,114 - 188,114
$ 2,087,535 $ 58,991 $ 188,114 $ 35,168 $ 2,369,808
----- End of picture text -----

B. The Group has recognised the following revenue-related contract assets and liabilities:

Contract assets - current Contract liabilities - current	September 30, 2025 77,480 $ 75,940 $	December 31, 2024 29,397 $ 119,396 $	September 30, 2024 - $ 157,755 $	January 1, 2024
				- $
				110,967 $

C. The revenue recognised that was included in the contract liability balance at the beginning of the period amounted to $29,237, $6,393, $85,091 and $64,416 for the three-month and nine-month periods ended September 30, 2025 and 2024, respectively.

(18) INTEREST INCOME

For the three-month periods ended September 30,

2025 2024

Interest income from bank deposits $ 12,009 $ 15,064 For the nine-month periods ended September 30, 2025 2024 Interest income from bank deposits $ 41,125 $ 45,238

~32~

(19) OTHER INCOME

For the three-month periods ended September 30,

			2025			2024
Dividend income		$	25,615		$	-
Government grants income			472			2,078
Other income			638			298
		$	26,725		$	2,376
	For thenine-monthperiods				ended	September30,
			2025			2024
Dividend income		$	25,615		$	-
Government grants income			564			2,078
Other income			1,423			2,368
		$	27,602		$	4,446
OTHER GAINS AND LOSSES
	For thethree-monthperiods ended					September 30,
			2025			2024
Net (loss) gain on financial assets/liabilities at	($		9,939)		$	1,506
fair value through profit or loss
Loss on disposal of property, plant
and equipment	(		100)	(		3,588)
Net currency exchange gain (loss)			13,872	(		10,958)
Others	(		1,063)	(		365)
		$	2,770	($		13,405)
	For thenine-monthperiods				ended	September30,
			2025			2024
Net gain (loss) on financial assets/liabilities at		$	2,884	($		21,178)
fair value through profit or loss
Gain on reversal of impairment loss			63			-
Gain (loss) on disposal of property, plant
and equipment			3	(		4,278)
Net currency exchange (loss) gain	(		40,149)			28,626
Others	(		1,881)	(		2,448)
	($		39,080)		$	722

(20) OTHER GAINS AND LOSSES

~33~

(21) FINANCE COSTS

For the three-month periods ended September 30, 2025 2024

	2025 2024	2024
Interest expense: Bank loans Interest on lease liabilities Interest expense: Bank loans Interest on lease liabilities	888 $ 119 $ 1,820 1,815 2,708 $ 1,934 $ 2025 2024 1,632 $ 528 $ 5,476 5,473 7,108 $ 6,001 $ For thenine-monthperiods ended September30,	119 $ 1,815
		1,934 $

(22) EXPENSES BY NATURE

EXPENSES BY NATURE
Employee benefit expenses Depreciation of property, plant and equipment Depreciation of right-of-use assets Amortisation Employee benefit expenses Depreciation of property, plant and equipment Depreciation of right-of-use assets Amortisation Employee benefit expenses Depreciation of property, plant and equipment Depreciation of right-of-use assets Amortisation	For thethree-monthperiod ended September 30,2025
	Operating costs Operating expenses Total 160,006 $ 87,276 $ 247,282 $ 102,198 18,099 120,297 - 5,310 5,310 878 4,276 5,154 For the three-month period ended September 30, 2024		Total
	Operating costs Operating expenses Total 166,166 $ 78,635 $ 244,801 $ 99,085 18,042 117,127 - 4,315 4,315 680 1,799 2,479 For the nine-month period ended September 30, 2025		Total
	Operating costs 485,362 $ 302,262 - 2,817	Operating expenses 257,787 $ 52,547 15,288 12,430	Total
			743,149 $ 354,809 15,288 15,247

~34~

Operating costs Operating expenses Total 499,039 $ 253,946 $ 752,985 $ 293,108 51,893 345,001 - 12,928 12,928 2,062 4,814 6,876 For thenine-monthperiod ended September30,2024 For thethree-monthperiod ended September30,2025	Operating costs Operating expenses Total 499,039 $ 253,946 $ 752,985 $ 293,108 51,893 345,001 - 12,928 12,928 2,062 4,814 6,876 For thenine-monthperiod ended September30,2024 For thethree-monthperiod ended September30,2025	Operating costs Operating expenses Total 499,039 $ 253,946 $ 752,985 $ 293,108 51,893 345,001 - 12,928 12,928 2,062 4,814 6,876 For thenine-monthperiod ended September30,2024 For thethree-monthperiod ended September30,2025
Operating costs Operating expenses Total 134,042 $ 73,138 $ 207,180 $ 11,981 5,673 17,654 7,425 3,637 11,062 6,558 4,828 11,386 160,006 $ 87,276 $ 247,282 $ For thethree-monthperiod ended September30,2024		Total
		207,180 $ 17,654 11,062 11,386
		247,282 $
Operating costs Operating expenses Total 140,373 $ 65,268 $ 205,641 $ 11,617 5,066 16,683 7,382 3,300 10,682 6,794 5,001 11,795 166,166 $ 78,635 $ 244,801 $ For the nine-month period ended September 30, 2025		Total
		205,641 $ 16,683 10,682 11,795
		244,801 $
Operating costs Operating expenses Total 405,212 $ 214,393 $ 619,605 $ 37,138 17,384 54,522 22,792 10,489 33,281 20,220 15,521 35,741 485,362 $ 257,787 $ 743,149 $ For thenine-monthperiod ended September30,2024		Total
		619,605 $ 54,522 33,281 35,741
		743,149 $
Operating costs 420,602 $ 36,256 22,532 19,649 499,039 $	Operating expenses 213,705 $ 16,302 9,332 14,607 253,946 $	Total 634,307 $ 52,558 31,864 34,256
		752,985 $

(23) EMPLOYEE BENEFIT EXPENSES

~35~

A. According to the Articles of Incorporation of the Company, a ratio of distributable profit of the current year, after covering accumulated losses, shall be distributed as employees’ compensation and directors’ remuneration. The ratio shall not be lower than 2% for employees’ compensation (compensation for grassroots employees shall not be less than 1%) and shall not be higher than 2% for directors’ remuneration.
B. For the three-month and nine-month periods ended September 30, 2025 and 2024, the employees’ compensation was accrued at $1,916, $3,392, $12,337 and $29,916, respectively, while the directors’ remuneration was accrued at $248, $433, $1,531 and $3,872, respectively. The aforementioned amounts were recognised in salary expenses and were estimated and accrued based on the earnings of current period and the percentage specified in the Articles of Incorporation of the Company. The actual amount approved at the Board of Directors’ meeting for employees’ compensation and directors’ remuneration for 2024 was $46,723, which was the same as the amount recognised in the 2024 financial statements. The employees’ compensation was distributed in the form of cash for 2024. Information about the appropriation of employees’ compensation and directors’ remuneration by the Company as resolved by the Board of Directors will be posted in the “Market Observation Post System” at the website of the Taiwan Stock Exchange.

(24) INCOME TAX

A. Income tax expense

Components of income tax expense:

For the three-month periods ended September 30,

( Total current tax ( Income tax expense Origination and reversal of temporary differences Current income tax: Income tax for the period Over provision of prior year’s income tax Deferred income tax:	2025 16,690 $ 479) 16,211 12,479) ( 3,732 $	2024 12,814 $ - 12,814 5,980) 6,834 $

~36~

For the nine-month periods ended September 30,

			2025			2024
Current income tax:
Income tax for the period		$	51,486		$	58,035
Over provision of
prior year’s income tax	(		96)	(		2,967)
Total current tax			51,390			55,068
Deferred income tax:
Origination and reversal of temporary
differences	(		23,648)			2,149
Income tax expense		$	27,742		$	57,217

B. The Company’s income tax returns through 2023 have been assessed and approved by the Tax Authority, and there were no disputes existing between the Company and the Authority as of November 3, 2025.

(25) EARNINGS PER SHARE (“EPS”)

November 3, 2025. EARNINGS PER SHARE (“EPS”)
Basic earnings per share Profit attributable to ordinary stockholders of the parent Diluted earnings per share Profit attributable to ordinary stockholders of the parent Assumed conversion of all dilutive potential ordinary shares Employees’ stock options Employees’ compensation Profit attributable to ordinary stockholders of the parent plus assumed conversion of all dilutive potential ordinary shares	For thethree-monthperiod ended September		30,2025
	Amount after tax 15,446 $ 15,446 $ - - 15,446 $	Weighted average number of shares outstanding (sharesin thousands) 790,739 790,739 - 655 791,394	EPS (indollars)
			0.02 $
			0.02 $

~37~

For thethree-monthperiod ended September	For thethree-monthperiod ended September	30,2024
Weighted average number of shares outstanding Amount after tax (sharesin thousands) 27,103 $ 790,739 27,103 $ 790,739 - - - 1,178 27,103 $ 791,917 For thenine-monthperiod ended September		EPS (indollars)
		0.03 $
		0.03 $
		30,2025
Amount after tax 95,670 $ 95,670 $ - - 95,670 $	Weighted average number of shares outstanding (sharesin thousands) 790,739 790,739 - 1,032 791,771	EPS (indollars)
		0.12 $
		0.12 $

~38~

Basic earnings per share Profit attributable to ordinary stockholders of the parent Diluted earnings per share Profit attributable to ordinary stockholders of the parent Assumed conversion of all dilutive potential ordinary shares Employees’ stock options Employees’ compensation Profit attributable to ordinary stockholders of the parent plus assumed conversion of all dilutive potential ordinary shares	Weighted average number of shares outstanding Amount after tax (sharesin thousands) 242,008 $ 790,739 242,008 $ 790,739 - - - 1,471 242,008 $ 792,210 For thenine-monthperiod ended September	EPS (indollars) 30,2024
		0.31 $
		0.31 $

For the three-month and nine-month periods ended September 30, 2025 and 2024, some abovementioned stock options issued were anti-dilutive; therefore they were not included in the diluted EPS calculation.

(26) SUPPLEMENTAL CASH FLOW INFORMATION

A. Investing activities with partial cash payments:

Investing activities with partial cash payments:
	For thenine-monthperiods ended September30,
		2025				2024
Purchase of property, plant and equipment	$		47,412		$		46,130
Add: Beginning balance of payable
on equipment (listed as “Other payables”)			102,971				56,759
Less: Ending balance of payable
on equipment (listed as “Other payables”)	(		37,298)	(			14,214)
Cash paid for acquisition of property, plant
and equipment	$		113,085		$		88,675

~39~

	For thenine-monthperiods ended September30,	For thenine-monthperiods ended September30,	For thenine-monthperiods ended September30,	For thenine-monthperiods ended September30,	For thenine-monthperiods ended September30,	For thenine-monthperiods ended September30,
			2025			2024
Purchase of prepayments for equipment		$	48,229		$	159,800
Add: Beginning balance of payable
on equipment (listed as “Other payables”)			51,251			-
Less: Ending balance of payable
on equipment (listed as “Other payables”)	(		3,284)	(		17,821)
Cash paid for prepayments for equipment		$	96,196		$	141,979

B. Operating and investing activities with no cash flow effects:

				For thenine-monthperiods ended	For thenine-monthperiods ended	For thenine-monthperiods ended	For thenine-monthperiods ended	For thenine-monthperiods ended	For thenine-monthperiods ended	September	30,
					2025				2024
Inventory reclassified to prepayments				$			3,820	$			-
Property, plant and equipment reclassified to
intangible assets				$			1,278	$			-
Property, plant and equipment reclassified to
other non-current assets - others				$			5,755	$			-
Prepayments for equipment reclassified to
property, plant and equipment				$			59,487	$		201,670
Prepayments for equipment reclassified to
other non-current assets - others				$			51,732	$			-
CHANGES IN LIABILITIES FROM FINANCING ACTIVITIES
							Guarantee		Liabilities from
For the nine-month period ended		Short-term			Lease		deposits			financing
September30,2025		borrowings			liabilities		received		activities-gross
At January 1, 2025	$	35,563		$	639,980		$	3,992	$	679,535
Changes in cash flow from
financing activities		106,664	(		11,797)		(	181)		94,686
Impact of changes in
foreign exchange rate	(	2,750)				-	(	113)	(	2,863)
Changes in other
non-cash items		-			8,241			-		8,241
At September 30, 2025	$	139,477		$	636,424		$	3,698	$	779,599

(27) CHANGES IN LIABILITIES FROM FINANCING ACTIVITIES

~40~

For the nine-month period ended September 30, 2024 At January 1, 2024 Changes in cash flow from financing activities Impact of changes in foreign exchange rate Changes in other non-cash items At September 30, 2024	Guarantee Liabilities from Short-term Lease deposits financing borrowings liabilities received activities-gross 32,137 $ 587,787 $ 1,297 $ 621,221 $ 2,166 9,350) ( 2,974 4,210) ( 1,401 - 72 1,473 - 61,985 - 61,985 35,704 $ 640,422 $ 4,343 $ 680,469 $	Liabilities from financing activities-gross

7. RELATED PARTY TRANSACTIONS

(1) Parent and ultimate controlling party

The ultimate parent and ultimate controlling party of the Company is Uni-President Enterprises Corp.

(2) Names of related parties and relationship

Names of related parties

Uni-President Enterprises Corp. President Securities Corp. President Transnet Corp. President Tokyo Corp. Mech-President Corp. President Chain Store Corp. President Chain Store Tokyo Marketing Corp. President Information Corp. Duskin Serve Taiwan Co., Ltd. Uni-President Enterprises (China) Investment Corp. Uni-President Shanghai Pearly Century Co., Ltd.

Relationship with the Company Ultimate parent company Associate of ultimate parent company Associate of ultimate parent company Associate of ultimate parent company Associate of ultimate parent company Associate of ultimate parent company Associate of ultimate parent company Associate of ultimate parent company Associate of ultimate parent company Associate of ultimate parent company Associate of ultimate parent company

(3) Significant transactions and balances with related parties

A. Property transactions

Property transactions
Acquisition of property, plant and equipment `－`Ultimate parent company `－`Associate of ultimate parent company	For thenine-monthperiods ended September30,
	2025 41 $ 286 327 $	2024
		- $ 1,017
		1,017 $

There was no such situation for the three-month periods ended September 30, 2025 and 2024.

~41~

B. Other expenses

For the three-month periods ended September 30,

Management service fees:

－ Ultimate parent company

－ Associate of ultimate parent company

For thethree-monthperio	ds ended September30,
2025 1 $ 726 727 $	2024 51 $ 764
	815 $

Management service fees: － Ultimate parent company

－ Associate of ultimate parent company

$ $	1 51 $ 726 764 727 815 $	1 51 $ 726 764 727 815 $	1 51 $ 726 764 727 815 $
For	thenine-monthperiods ended September30,
	2025		2024
$	2,235	$	1,963
	2,229		2,285

$	4,464	$	4,248

(4) Key management compensation

Key management compensation	Key management compensation	Key management compensation
2025 2024 Salaries and other short-term employee benefits 10,650 $ 11,344 $ Post-employment benefits 120 121 Termination benefits 400 400 11,170 $ 11,865 $ 2025 2024 Salaries and other short-term employee benefits 32,606 $ 40,176 $ Post-employment benefits 361 435 Termination benefits 1,200 1,196 34,167 $ 41,807 $ For thethree-monthperiods ended September30, For thenine-monthperiods ended September30,
	2025 2024 10,650 $ 11,344 $ 120 121 400 400 11,170 $ 11,865 $ For thenine-monthperiods ended September30,	2024
		11,344 $ 121 400
		11,865 $
	2025 32,606 $ 361 1,200 34,167 $	2024
		40,176 $ 435 1,196
		41,807 $

8. PLEDGED ASSETS

Details of the Group’s assets pledged as collateral are as follows:

Assets Pledged time deposits (Note)	September30,2025 29,270 $	December31,2024 30,940 $	September30,2024 30,940 $	Purpose ofcollateral
				Performance guarantee, customs duty and guarantee for credit card

Note: Listed as “Other financial assets - non-current”.

~42~

9. SIGNIFICANT CONTINGENT LIABILITIES AND UNRECOGNISED CONTRACT COMMITMENTS

(1) As of September 30, 2025, December 31, 2024, and September 30, 2024, the Group’s remaining balance due for construction in progress and prepayments for equipment were $15,563, $43,512 and $97,955, respectively.
(2) The amounts of endorsements and guarantees for subsidiaries were as follows:

Nature September 30, 2025 December 31, 2024 September 30, 2024 SciAnda (Changshu) Guarantee for Pharmaceuticals, financing amount $ - $ 179,661 $ 180,375

As of September 30, 2025, December 31, 2024, and September 30, 2024, the actual amount drawn down for endorsements and guarantees to subsidiaries was $ － .

10. SIGNIFICANT DISASTER LOSS

None.

11. SIGNIFICANT EVENTS AFTER THE BALANCE SHEET DATE

None.

12. OTHERS

(1) Capital management

The Group’s objectives on managing capital are to safeguard the Group’s ability to continue as a going concern in order to provide returns for shareholders, to maintain an optimal capital structure, to reduce the cost of capital and to maintain an adequate capital structure to enable the expansion and enhancement of equipment. In order to maintain or adjust the capital structure, the Group may adjust the amount of dividends paid to shareholders, return of capital to shareholders, and issue new shares or sell assets to reduce debts.

(2) Financial instruments

A. Financial instruments

For details of the Group’s financial instruments by category, refer to Note 6.

B. Risk management policies
(a) The Group’s activities expose it to a variety of financial risks: market risk (including foreign exchange risk, price risk and interest rate risk), credit risk and liquidity risk.
(b) The Group’s treasury identifies, evaluates and hedges financial risks closely with the Group’s operating units. The Board provides written principles for overall risk management, as well as written policies covering specific areas and matters, such as use of derivative financial instruments and investment of excess liquidity.
(c) Information about derivative financial instruments that are used to hedge financial risk are provided in Note 6(2), “Financial assets and liabilities at fair value through profit or loss”.

~43~

C. Significant financial risks and degrees of financial risks
(a) Market risk
- I. Foreign exchange rate risk
- (i) The Group operates internationally and is exposed to foreign exchange risk arising from the transactions of the Company and its subsidiaries used in various functional currency, primarily with respect to USD. Foreign exchange risk arises from future commercial transactions and recognised assets and liabilities.
- (ii) To manage their foreign exchange risk arising from future commercial transactions and recognised assets and liabilities, entities in the Group are required to hedge their foreign exchange risk exposure using forward foreign exchange contracts. However, the Group does not adopt hedging accounting. Details of financial assets or liabilities at fair value through profit or loss are provided in Note 6(2), “Financial assets and liabilities at fair value through profit or loss”.
- (iii) The Group’s businesses involve some non-functional currency operations (the Company’s and certain subsidiaries’ functional currency: NTD; other subsidiaries’ functional currency: CNY). The information on assets and liabilities denominated in foreign currencies whose values would be materially affected by the exchange rate fluctuations is as follows:

Foreign currency amount (in thousands) Exchangerate (Foreign currency: functional currency) Financial assets Monetary items USD:NTD 14,396 $ 30.45 Financial liabilities Monetary items USD:NTD 726 30.45 GBP:NTD 99 40.97 EUR:NTD 47 35.77 CHF:NTD 40 38.25 September30,2025	Book value (NTD)
	438,358 $ 22,107 4,056 1,681 1,530

~44~

December31,2024	December31,2024	Book value (NTD) 626,617 $ 39,651 23,346 7,126 1,639 1,105 Book value (NTD) 515,990 $
Foreign currency amount(in thousands) Exchangerate 19,110 $ 32.79 8,827 4.492 712 32.79 173 41.19 48 34.14 5,264 0.210 September30,2024
Foreign currency amount(in thousands) 16,303 $ 319 571 104	Exchangerate 31.65 7.019 31.65 35.38
		10,096
		18,072 3,680

(iv) As of September 30, 2025 and 2024, if the NTD:USD exchange rate appreciates/ depreciates by 5% with all other factors remaining constant, the Group’s net profit after tax for the nine-month periods ended September 30, 2025 and 2024 would increase/decrease by $16,650 and $19,917, respectively. If the exchange rate of NTD to other currencies had appreciated/depreciated by 5% with all other factors remaining constant, the effect on the Group’s net profit after tax for the nine-month periods ended September 30, 2025 and 2024 is immaterial.

(v) Total exchange gain (loss) including realised and unrealised arising from significant foreign exchange variation on the monetary items held by the Group for the three-month and nine-month periods ended September 30, 2025 and 2024 amounted to $13,872, ($10,958), ($40,149) and $28,626, respectively.

~45~

II. Price risk

(i) The Group’s equity securities, which are exposed to price risk, are the held financial assets and liabilities at fair value through profit or loss and financial assets at fair value through other comprehensive income. To manage its price risk arising from investments in equity securities, the Group diversifies its portfolio and set stop-loss amounts for these instruments. The Group expects no significant market risk.
(ii)The Group’s investments in equity securities comprise equity securities issued by the domestic and foreign companies. The prices of equity securities would change due to the change of the future value of investee companies. If the prices of these equity securities had increase/decrease by 5% with all other variables held constant, other components of equity would have increased/decreased by $97,606 and $3,728 for the nine-month periods ended September 30, 2025 and 2024, respectively, as a result of other comprehensive income on equity investments classified as at fair value through other comprehensive income.
III. Cash flow and fair value interest rate risk
(i) The Group’s main interest rate risk arises from short-term borrowings with variable rates and exposes the Group to cash flow interest rate risk. During the nine-month periods ended September 30, 2025 and 2024, the Group’s borrowings at variable rate were denominated in CNY.
(ii) The Group’s borrowings are measured at amortised cost. The borrowings are periodically contractually repriced and to that extent are also exposed to the risk of future changes in market interest rates.
(iii) If the borrowing interest rates had increased/decreased by 10% with all other variables held constant, the effect on post-tax profit for the nine-month periods ended September 30, 2025 and 2024 is immaterial.
(b) Credit risk
I. Credit risk refers to the risk of financial loss to the Group arising from default by the clients or counterparties of financial instruments on the contract obligations. The main factor is that counterparties could not repay in full the accounts receivable based on the agreed terms.
II. The Group manages its credit risk taking into consideration the entire group’s concern. For banks and financial institutions, only independently rated parties with a minimum rating of 'A' are accepted. According to the Group’s credit policy, each local entity in the Group is responsible for managing and analysing the credit risk for each of their new clients before standard payment and delivery terms and conditions are offered. Internal risk control assesses the credit quality of the customers, taking into account their financial position, past experience and other factors. Individual risk limits are set based on internal or external ratings in accordance with limits set by the Board of Directors. The utilisation of credit

~46~

limits is regularly monitored.

III. The Group adopts the following assumption under IFRS 9: If the contract payments were past due over 30 days based on the terms, there has been a significant increase in credit risk on that instrument since initial recognition.
IV. The Group manages its credit risk, whereby if the contract payments are past due over 180 days based on the terms, there has been impairment.
V. The Group classifies customers’ accounts receivable in accordance with the credit rating of the customer and credit risk on trade. The Group applies the simplified approach using the provision matrix to estimate expected credit loss, and use the forecastability to adjust historical and timely information to assess the default possibility of accounts receivable. Movements in relation to the Group applying the simplified approach to provide loss allowance for accounts receivable are as follows:

		For the nine-month periods ended September 30,	For the nine-month periods ended September 30,	For the nine-month periods ended September 30,	For the nine-month periods ended September 30,	For the nine-month periods ended September 30,
			2025			2024
At January 1		$		1,904	$	231
Expected credit (gain) loss	(			1,790)		1,681
Impact of foreign exchange rate				-		5
At September 30		$		114	$	1,917

(c) Liquidity risk

I. Cash flow forecasting is performed by the Group’s treasury department which monitors rolling forecasts of the Group’s liquidity requirements to ensure it has sufficient cash to meet operational needs while maintaining sufficient headroom on its undrawn committed borrowing facilities at all times so that the Group does not breach borrowing limits or covenants (where applicable) on any of its borrowing facilities.
II. The Group has undrawn borrowing facilities amounting to $4,992,542, $4,970,318 and $5,067,660 as of September 30, 2025, December 31, 2024, and September 30, 2024, respectively.
III. The following table comprises the Group’s non-derivative financial liabilities and derivative financial liabilities with gross-amount settlement that are grouped by their maturity. Non-derivative financial liabilities are analysed from the balance sheet date to the contract maturity date, and derivative financial liabilities are analysed from the balance sheet date to the expected maturity date. The amounts disclosed in the table are the contractual undiscounted cash flows.

~47~

September30,2025 Short-term borrowings Accounts payable Other payables Lease liabilities Guarantee deposits received Derivative financial liabilities: Forward exchange contracts December31,2024 Short-term borrowings Notes payable Accounts payable Other payables Lease liabilities Guarantee deposits received Derivative financial liabilities: Forward exchange contracts September30,2024 Short-term borrowings Notes payable Accounts payable Other payables Lease liabilities Guarantee deposits received Non-derivative financial liabilities: Non-derivative financial liabilities: Non-derivative financial liabilities:	Less than 1year 142,010 $ 112,017 314,652 23,963 1,629 2,107 Less than 1year 36,174 $ 1,211 80,959 498,191 19,764 - 1,225 Less than 1year 36,581 $ 1,603 126,966 341,918 18,398 -	Between 1 and2years - $ - - 20,148 2,069 - Between 1 and2years - $ - - - 19,422 3,992 - Between 1 and2years - $ - - - 18,398 4,343	Between 2 and 5 years - $ - - 55,195 - - Between 2 and 5 years - $ - - - 55,195 - - Between 2 and 5 years - $ - - - 55,195 -	More than 5 years
				- $ - - 703,730 - - More than 5 years
				- $ - - - 717,529 - - More than 5 years
				- $ - - - 722,128 -

(3) Fair value information

A. The different levels that the inputs to valuation techniques are used to measure fair value of financial and non-financial instruments have been defined as follows:

Level 1: Quoted prices (unadjusted) in active markets for identical assets or liabilities that the entity can access at the measurement date. A market is regarded as active where a market in which transactions for the asset or liability take place with sufficient frequency and volume to provide pricing information on an ongoing basis.

~48~

Level 2: Inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly. The fair value of the Group’s investment in private placement of emerging stocks and foreign exchange contracts is included in Level 2.
Level 3: Unobservable inputs for the asset or liability. The fair value of the Group’s investment in equity investment without active market is included in Level 3.
B. Financial instruments not measured at fair value

The carrying amounts of cash and cash equivalents, contract assets, accounts receivable, other receivables, guarantee deposits paid, other financial assets - non-current, short-term borrowings, notes payable, accounts payable, other payables and guarantee deposits received are approximate to their fair values.

C. The related information on financial instruments measured at fair value by level on the basis of the nature, characteristics and risks of the assets and liabilities are as follows:

September30,2025 Assets: Recurring fair value measurements Financial assets at fair value through other comprehensive income Equity securities Liabilities: Recurring fair value measurements Financial liabilities at fair value through profit or loss Derivative instruments December 31,2024 Assets: Recurring fair value measurements Financial assets at fair value through other comprehensive income Equity securities Liabilities: Financial liabilities at fair value through profit or loss Derivative instruments	Level 1 - $ - $ Level 1 - $ - $	Level 2 1,896,398 $ 2,107 $ Level 2 - $ 1,225 $	Level3 55,715 $ - $ Level 3 70,134 $ - $	Total
				1,952,113 $
				2,107 $
				Total
				70,134 $
				1,225 $

~49~

==> picture [463 x 139] intentionally omitted <==

----- Start of picture text -----

September 30, 2024 Level 1 Level 2 Level 3 Total
Assets:
Recurring fair value measurements
Financial assets at fair value through
profit or loss
Derivative instruments $ - $ 1,974 $ - $ 1,974
Financial assets at fair value through
other comprehensive income
- -
Equity securities $ $ $ 74,564 $ 74,564
----- End of picture text -----

D. The methods and assumptions the Group used to measure fair value are as follows:
(a) The fair value of other financial instruments is measured by using valuation techniques or by reference to counterparty quotes. The fair value of financial instruments measured by using valuation techniques can be referred to current fair value of instruments with similar terms and characteristics in substance, discounted cash flow method or other valuation methods, including calculated by applying model using market information available at the consolidated balance sheet date.
(b) When assessing non-standard and low-complexity financial instruments, for example, debt instruments without active market, interest rate swap contracts, foreign exchange swap contracts and options, the Group adopts valuation technique that is widely used by market participants. The inputs used in the valuation method to measure these financial instruments are normally observable in the market.
(c) Forward foreign exchange contracts are usually valued based on the current forward exchange rate.
E. For the nine-month periods ended September 30, 2025 and 2024, there was no transfer between Level 1 and Level 2.
F. The following chart is the movement of Level 3 for the nine-month periods ended September 30, 2025 and 2024:

2025 and 2024:
At January 1 (Loss) gain recognised in other comprehensive income ( At September 30	For thenine-monthperiods ended September30,
	2025 Equityinstrument 70,134 $ 14,419) 55,715 $	2024
		Equityinstrument
		69,973 $ 4,591
		74,564 $

For the nine-month periods ended September 30, 2025 and 2024, there was no transfer in (out) of Level 3.

~50~

G. The Group’s valuation procedures for fair value measurements is categorised within Level 3, which is to verify independent fair value of financial instruments. Such assessment is to ensure the valuation results are reasonable by applying independent information to make results close to current market conditions, confirming the resource of information is independent, reliable and in line with other resources and represented as the exercisable price, and frequently assess to make any other necessary adjustments to the fair value.
H. The following is the qualitative information of significant unobservable inputs and sensitivity analysis of changes in significant unobservable inputs to valuation model used in Level 3 fair value measurement:

Valuation technique	Significant unobservable input	Range (weighted average)	Relationship of inputs to fairvalue
Net asset value Valuation technique	Discount for lack of marketability Significant unobservable input	50% Range (weighted average)	The higher the discount for lack of marketability, the lower the fair value Relationship of inputs to fairvalue
Net asset value Valuation technique	Discount for lack of marketability Significant unobservable input	50% Range (weighted average)	The higher the discount for lack of marketability, the lower the fair value Relationship of inputs to fairvalue
Net asset value	Discount for lack of marketability	50%	The higher the discount for lack of marketability, the lower the fair value

~51~

I. The Group has carefully assessed the valuation models and assumptions used to measure fair value. However, use of different valuation models or assumptions may result in different measurement. If the discount for lack of marketability increased or decreased by 1% for Level 3, the effect on other comprehensive income for the nine-month periods ended September 30, 2025 and 2024 is immaterial.

13. SUPPLEMENTARY DISCLOSURES

According to the current regulatory requirements, the Group is only required to disclose the information for the nine-month period ended September 30, 2025.

(1) Significant transactions information

A. Loans to others: None.
B. Provision of endorsements and guarantees to others: Refer to table 1.
C. Holding of significant marketable securities at the end of the period (not including subsidiaries, associates and joint ventures): Refer to table 2.
D. Purchases or sales of goods from or to related parties reaching $100 million or 20% of paid-in capital or more: Refer to table 3.
E. Receivables from related parties reaching $100 million or 20% of paid-in capital or more: None.
F. Significant inter-company transactions during the reporting period: Refer to table 4.

(2) Information on investees

Names, locations and other information of investee companies (not including investees in Mainland China): Refer to table 5.

(3) Information on investments in Mainland China

A. Basic information: Refer to table 6.
B. Significant transactions, either directly or indirectly through a third area, with investee companies in the Mainland Area: Refer to table 1 and table 4.

14. SEGMENT INFORMATION

(1) General information

The management of the Group has identified the operating segments based on how the Company’s Chief Operating Decision-Maker regularly reviews information in order to make decisions. The Chief Operating Decision-Maker manages the Group’s business from geographical and functional perspectives. Geographically, the Group focuses on its sales business in the U.S., Europe and Asia. In addition, the Group categorised its business units into manufacture, sales, research and development and investment management functions, and combines its segments that meet the disclosure threshold as “Others”.

~52~

(2) Segment information

The segment information provided to the Chief Operating Decision-Maker for the reportable segments is as follows:

segments is as follows:
Segment revenue Revenue from internal customers Revenue from external customers `－`API Income －Injection Product Income `－`Technical Service Income `－`Other Operating Income Interest income Depreciation and amortisation Interest expense Income (loss) from segment before income tax Segment assets Other acquisition of non-current assets Segment liabilities Segment revenue Revenue from internal customers Revenue from external customers `－`API Income －Injection Product Income `－`Technical Service Income `－`Other Operating Income Interest income Depreciation and amortisation Interest expense Income from segment before income tax Segment assets Other acquisition of non-current assets Segment liabilities	For thenine-monthperiod ended September 30,2025
	ScinoPharm SciAnda (Changshu) Taiwan,Ltd. PharmaceuticalsLtd. Others Total 2,124,141 $ 282,454 $ 12,918 $ 2,419,513 $ 15 251,982 12,135 264,132 2,124,126 30,472 783 2,155,381 1,806,259 25,635 - 1,831,894 122,175 - - 122,175 165,661 4,837 783 171,281 30,031 - - 30,031 40,808 222 95 41,125 298,125 86,621 598 385,344 5,476 1,632 - 7,108 225,397 101,201) ( 396 124,592 10,757,769 1,636,095 24,943 12,418,807 84,018 17,930 40 101,988 1,141,127 205,688 973 1,347,788 For thenine-monthperiod ended September 30,2024			Total
	ScinoPharm Taiwan,Ltd. 2,176,669 $ 9,571 2,167,098 1,890,615 58,991 182,324 35,168 44,783 280,726 5,473 277,175 10,126,488 121,954 1,230,305	SciAnda (Changshu) PharmaceuticalsLtd. 518,626 $ 317,323 201,303 196,868 - 4,435 - 319 83,259 528 34,537 1,747,161 93,938 129,610	Others 12,076 $ 10,669 1,407 52 - 1,355 - 136 820 - 1,267 33,799 18 9,576	Total
				2,707,371 $ 337,563 2,369,808 2,087,535 58,991 188,114 35,168 45,238 364,805 6,001 312,979 11,907,448 215,910 1,369,491

~53~

(3) Reconciliation for segment

A. The sales between segments were at arms’ length. The external revenues reported to the Chief Operating Decision-Maker adopt the same measurement basis for revenues in the statement of comprehensive income. The reconciliations of pre-tax income between reportable segments and continuing operations were as follows :

		For thenine-monthperiods ended September30,	For thenine-monthperiods ended September30,	For thenine-monthperiods ended September30,	For thenine-monthperiods ended September30,	For thenine-monthperiods ended September30,
			2025			2024
Reportable segments profit before		$	124,196		$	311,712
income tax
Other segments income before income			396			1,267
tax
Internal segments transaction elimination	(		1,180)	(		13,754)
Profit before income tax		$	123,412		$	299,225

B. The amount of total assets provided to the Chief Operating Decision-Maker adopts the same measurement for assets in the Group’s financial statements. A reconciliation of assets of reportable segments and total assets is as follows:

September30,2025 Assets of reportable segments 12,393,864 $ Assets of other operating segments 24,943 Internal segment transaction elimination 106,858) ( ( Total assets 12,311,949 $	September 30, 2024 11,873,649 $ 33,799 123,144) 11,784,304 $

C. The amount of total liabilities provided to the Chief Operating Decision-Maker adopts the same measurement for liabilities in the Group’s financial statements. A reconciliation of liabilities of reportable segments and total liabilities is as follows:

Liabilities of reportable segments Liabilities of other operating segments Internal segment transaction elimination ( Total liabilities	September30,2025 1,346,815 $ 973 28,785) ( 1,319,003 $	September30,2024 1,359,915 $ 9,576 25,093) 1,344,398 $

~54~

ScinoPharm Taiwan, Ltd. and Subsidiaries

Table 1

Expressed in thousands of NTD

Provision of endorsements and guarantees to others

For the nine-month period ended September 30, 2025

Number	Endorser/ guarantor	Party being endorsed/guaranteed	Party being endorsed/guaranteed	Limit on endorsements/ guarantees provided for a single party （Note 2）	Maximum outstanding endorsement/ guarantee amount during theperiod	Outstanding endorsement/ guarantee amount at September 30, 2025	Actual amount drawn down	Amount of endorsements/ guarantees secured with collateral	Ratio of accumulated endorsement/ guarantee amount to net asset value of the endorser/ guarantor company	Ceiling on total amount of endorsements/ guarantees provided （Note 2）	Provision of endorsements/ guarantees by parent company to subsidiary	Provision of endorsements/ guarantees by subsidiary to parent company	Provision of endorsements/ guarantees to the party in Mainland China	Footnote
		Companyname	Relationship with the endorser/ guarantor （Note1）
0	ScinoPharm Taiwan, Ltd.	SciAnda (Changshu) Pharmaceuticals, Ltd.	1	10,992,946 $	180,465 $	- $	- $	- $	-	10,992,946 $	Y	N	Y	`－`

Note 1: The following code represents the relationship with the Company:

1.A company in which the Company directly and indirectly holds 50% of the voting shares.
Note 2: 1.The limit of total amount of endorsement is 50% of the Company’s net worth, for 100% directly or indirectly owned subsidiaries, the maximum amount is 100% of its net worth.

The limit of total amount of the Group’s endorsement and guarantee is 100% of the Group’s net worth.

2.For any endorsement or guarantee provided by the Company due to business dealings, the amount of endorsement or guarantees shall be limited to the business dealing amount of the most recent year or the current year. The business dealing amount is product purchase or sale amount between the entities, whichever is higher.

Note 3: The numbers in the table that involves foreign currencies are expressed in New Taiwan Dollars according to the exchange rate posted on the date of the consolidated financial statements (CNY:NTD 1:4.27).

Table 1, Page 1

ScinoPharm Taiwan, Ltd. and Subsidiaries

Table 2

Expressed in thousands of NTD

Holding of significant marketable securities at the end of the period (not including subsidiaries, associates and joint ventures) September 30, 2025

Securitiesheld by	Marketable securities	Relationship with the securitiesissuer	General ledger account		As ofSeptember30,2025	As ofSeptember30,2025		Footnote
				Numberofshares	Bookvalue	Ownership (%)	Fairvalue
ScinoPharm Taiwan, Ltd.	Stocks: HANDA PHARMACEUTICALS, INC. Tanvex Biologics, Inc.	The Company is a director of HANDA PHARMACEUTICALS, INC. The Company is a director of Tanvex Biologics, Inc.	Financial assets at fair value through other comprehensive income - non-current Financial assets at fair value through other comprehensive income - non-current	17,000,000 28,800,000	1,896,398 $ 55,715	10.71% 16.84%	1,896,398 $ 55,715	`－` `－`

Table 2, Page 1

Table 3

Expressed in thousands of NTD

ScinoPharm Taiwan, Ltd. and Subsidiaries

Purchases or sales of goods from or to related parties reaching $100 million or 20% of paid-in capital or more For the nine-month period ended September 30, 2025

Purchaser/seller	Counterparty	Relationship with the counterparty			Transaction		Differences in t compared t trans	ransaction terms o third party actions	Notes/account	s receivable(payable)	Footnote
			Purchases(sales)	Amount	Percentage of total purchases(sales)	Credit term	Unitprice	Credit term	Balance	Percentage of total notes/accounts receivable(payable)
ScinoPharm Taiwan, Ltd. SciAnda (Changshu) Pharmaceuticals, Ltd.	SciAnda (Changshu) Pharmaceuticals, Ltd. ScinoPharm Taiwan, Ltd.	Subsidary The Company	Purchases (Sales)	255,744 $ 255,744) (	39% (91%)	Closes its accounts 90 days from the end of each month Closes its accounts 90 days from the end of each month	- $ -	`－` `－`	20,948) ($ 20,948	(16%) 44%	`－` `－`

Table 3, Page 1

ScinoPharm Taiwan, Ltd. and Subsidiaries

Table 4

Expressed in thousands of NTD

- Significant inter company transactions during the reporting period For the nine-month period ended September 30, 2025

Number (Note2)	Companyname	Counterparty	Relationship (Note 3)		Transactions	Transactions
				General ledger account	Amount	Transaction terms	Percentage of consolidated total operating revenues or total assets (Note4)
0	ScinoPharm Taiwan, Ltd.	SciAnda (Changshu) Pharmaceuticals, Ltd.	1 1	Purchases Accounts Payable	255,744 $ 20,948	Closes its accounts 90 days from the end of each month `－`	12% `－`

Note 1: Significant inter-company transactions during the reporting periods are not disclosed since these were corresponding transactions. Only transactions over NT$10 million are material.
Note 2: The numbers filled in for the transaction company in respect of inter-company transactions are as follows:
(1) Parent company is ‘0’.
(2) The subsidiaries are numbered in order starting from ‘1’.
Note 3: Relationship between transaction company and counterparty is classified into the following three categories:
(1) Parent company to subsidiary.
(2) Subsidiary to parent company.
(3) Subsidiary to subsidiary.
Note 4: Regarding percentage of transaction amount to consolidated total operating revenues or total assets, it is computed based on period-end balance of transaction to consolidated total assets for balance sheet accounts and based on accumulated transaction amount for the period to consolidated total operating revenues for income statement accounts.
Note 5: The numbers in the table that involves foreign currencies are expressed in New Taiwan Dollars according to the exchange rate posted on the date of the consolidated financial statements (CNY:NTD 1:4.27 ； USD:NTD 1:30.45).

Table 4, Page 1

ScinoPharm Taiwan, Ltd. and Subsidiaries

Expressed in thousands of NTD

Names, locations and other information of investee companies (not including investees in Mainland China) For the nine-month period ended September 30, 2025

Table 5

Investor	Investee	Location	Main business activities	Initial investment amount	Initial investment amount	Sharesheld	asatSeptember30,2025	asatSeptember30,2025	Net profit of the investee for the nine-month period ended September30,2025	Investment income recognised by the Company for the nine-month period ended September30,2025	Footnote
				Balance as at September30,2025	Balance as at December31,2024	Numberofshares	Ownership (%)	Bookvalue
ScinoPharm Taiwan, Ltd.	SPT International, Ltd. ScinoPharm Singapore Pte Ltd.	Tortola, British Virgin Islands Singapore	Professional investment Professional investment	3,614,585 $ -	3,614,585 $ -	118,524,644 2	100% 100%	1,376,068 $ 235	100,860) ($ 16	102,040) ($ 16	Subsidiary Subsidiary

Table 5, Page 1

ScinoPharm Taiwan, Ltd. and Subsidiaries

Expressed in thousands of NTD

Information on investments in Mainland China `－` Basic information

For the nine-month period ended September 30, 2025

Table 6

Investee in Mainland China	Main business activities	Paid-in capital	Investment method	Accumulated amount of remittance from Taiwan to Mainland China as of January 1, 2025	Amount remitted from Taiwan to Mainland China/ Amount remitted back to Taiwan for the nine-month period ended September 30,2025	Amount remitted from Taiwan to Mainland China/ Amount remitted back to Taiwan for the nine-month period ended September 30,2025	Accumulated amount of remittance from Taiwan to Mainland China as of September 30,2025	Net income of investee for the nine-month period ended September 30,2025	Ownership held by the Company (direct or indirect)	Investment income recognised by the Company for the nine-month period ended September 30,2025	Book value of investments in Mainland China as of September 30, 2025	Accumulated amount of investment income remitted back to Taiwan as of September 30, 2025	Footnote
					Remitted to Mainland China	Remitted back to Taiwan
SciAnda (Changshu) Pharmaceuticals, Ltd. SciAnda Shanghai Biochemical Technology, Ltd.	Research, development, and manufacture of API and new drugs, sales of self-produced products, etc. Import, export and sales of API and intermediates, etc.	3,546,843 $ 36,534	`（`Note 1`）` `（`Note 1`）`	3,538,453 $ 36,534	- $ -	- $ -	3,538,453 $ 36,534	101,201) ($ 707	100% 100%	101,201) ($ 707	1,430,407 $ 20,837	- $ -	Subsidary (Note 2) Subsidary (Note 3)

Accumulated amount of Investment amount approved by remittance from Taiwan to the Investment Commission of Ceiling on investments in Mainland Mainland China the Ministry of Economic China imposed by the Investment Company name as of September 30, 2025 Affairs (MOEA) Commission of MOEA (Note 4) ScinoPharm $ 3,612,254 $ 3,612,254 $ 6,595,768 Taiwan, Ltd.

Note 1: Indirect investment in Mainland China through a company set up in a third region, SPT International, Ltd.

Note 2: The investment income recognised by the Company for the nine-month period ended September 30, 2025 was based on reviewed financial statements of investee companies as of and for the nine-month period ended September 30, 2025. Note 3: The investment income recognised by the Company for the nine-month period ended September 30, 2025 was based on unreviewed financial statements of investee companies as of and for the nine-month period ended September 30, 2025. Note 4: The ceiling amount is 60% of the higher of net worth or consolidated net worth. Note 5: The numbers in the table that involves foreign currencies are expressed in New Taiwan Dollars according to the exchange rate posted on the date of the financial statements (USD:NTD 1:30.45).

Table 6, Page 1

AI assistant

SPT — Interim / Quarterly Report 2025

51922_rns_2025-12-10_09753a3e-79db-4e39-b395-c6457156a085.pdf

SCINOPHARM TAIWAN, LTD. AND SUBSIDIARIES

SEPTEMBER 30, 2025 AND 2024 CONSOLIDATED FINANCIAL STATEMENTS AND INDEPENDENT AUDITORS’ REVIEW REPORT TABLE OF CONTENTS

INDEPENDENT AUDITORS’ REVIEW REPORT TRANSLATED FROM CHINESE

Introduction

Scope of review

Basis for qualified conclusion

Qualified conclusion

SCINOPHARM TAIWAN, LTD. AND SUBSIDIARIES CONSOLIDATED BALANCE SHEETS

SEPTEMBER 30, 2025, DECEMBER 31, 2024 AND SEPTEMBER 30, 2024

SCINOPHARM TAIWAN, LTD. AND SUBSIDIARIES CONSOLIDATED BALANCE SHEETS SEPTEMBER 30, 2025, DECEMBER 31, 2024 AND SEPTEMBER 30, 2024

SCINOPHARM TAIWAN, LTD. AND SUBSIDIARIES CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME NINE MONTHS ENDED SEPTEMBER 30, 2025 AND 2024

SCINOPHARM TAIWAN, LTD. AND SUBSIDIARIES CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY NINE MONTHS ENDED SEPTEMBER 30, 2025 AND 2024

SCINOPHARM TAIWAN, LTD. AND SUBSIDIARIES CONSOLIDATED STATEMENTS OF CASH FLOWS NINE MONTHS ENDED SEPTEMBER 30, 2025 AND 2024

SCINOPHARM TAIWAN, LTD. AND SUBSIDIARIES CONSOLIDATED STATEMENTS OF CASH FLOWS NINE MONTHS ENDED SEPTEMBER 30, 2025 AND 2024

SCINOPHARM TAIWAN, LTD. AND SUBSIDIARIES NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS FOR THE NINE–MONTHS PERIODS ENDED SEPTEMBER 30, 2025 AND 2024 (Expressed in thousands of New Taiwan dollars, except as otherwise indicated)

1. HISTORY AND ORGANISATION

STATEMENTS AND PROCEDURES FOR AUTHORISATION

not yet adopted by the Group

4. SUMMARY OF MATERIAL ACCOUNTING POLICIES

(1) Compliance statement

(4) Employee benefits

Defined benefit plans

(5) Income tax

5. CRITICAL ACCOUNTING JUDGEMENTS, ESTIMATES AND KEY SOURCES OF ASSUMPTION UNCERTAINTY

6. DETAILS OF SIGNIFICANT ACCOUNTS

(1) CASH AND CASH EQUIVALENTS

(2) FINANCIAL ASSETS AND LIABILITIES AT FAIR VALUE THROUGH PROFIT OR LOSS

(3) ACCOUNTS RECEIVABLE, NET

(4) INVENTORIES

(6) PROPERTY, PLANT AND EQUIPMENT

E. The information on income and expense accounts relating to lease contracts is as follows:

(8) IMPAIRMENT OF NON-FINANCIAL ASSETS

(9) SHORT-TERM BORROWINGS

(10) OTHER PAYABLES

(11) PENSIONS

(12) SHARE CAPITAL

(13) CAPITAL RESERVES

(14) SHARE-BASED PAYMENT – EMPLOYEES’ COMPENSATION

B. Details of the share-based payment arrangements are as follows:

(15) RETAINED EARNINGS

(16) OTHER EQUITY ITEMS

(17) OPERATING REVENUE

(18) INTEREST INCOME

(19) OTHER INCOME

For the three-month periods ended September 30,

(20) OTHER GAINS AND LOSSES

(21) FINANCE COSTS

(22) EXPENSES BY NATURE

(23) EMPLOYEE BENEFIT EXPENSES

(24) INCOME TAX

A. Income tax expense

For the nine-month periods ended September 30,

(25) EARNINGS PER SHARE (“EPS”)

(26) SUPPLEMENTAL CASH FLOW INFORMATION

A. Investing activities with partial cash payments:

(27) CHANGES IN LIABILITIES FROM FINANCING ACTIVITIES

7. RELATED PARTY TRANSACTIONS

(1) Parent and ultimate controlling party

(2) Names of related parties and relationship

(3) Significant transactions and balances with related parties

A. Property transactions

B. Other expenses

For the three-month periods ended September 30,

(4) Key management compensation

8. PLEDGED ASSETS

9. SIGNIFICANT CONTINGENT LIABILITIES AND UNRECOGNISED CONTRACT COMMITMENTS

10. SIGNIFICANT DISASTER LOSS

11. SIGNIFICANT EVENTS AFTER THE BALANCE SHEET DATE

12. OTHERS

(1) Capital management

(2) Financial instruments

II. Price risk

(c) Liquidity risk

(3) Fair value information

13. SUPPLEMENTARY DISCLOSURES

(1) Significant transactions information

(2) Information on investees

SPT Interim / Quarterly Report 2025

Information on investments in Mainland China `－` Basic information